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Idiopathic or isolated clubfoot is a common orthopedic birth defect that affects 
approximately 135,000 children worldwide.  It is characterized by equinus, varus and 
adductus deformities of the ankle and foot.  Correction of clubfoot involves months of serial 
manipulations, castings and bracing, with surgical correction needed in forty percent of 
cases.  Multifactorial etiology has been suggested in numerous studies with both 
environmental and genetic factors playing an etiologic role.  Maternal smoking during 
pregnancy is the only common environmental factor that has consistently been shown to 
increase the risk for clubfoot.  Moreover, a positive family history of clubfoot and maternal 
smoking increases the risk of clubfoot twenty-fold.  These findings suggest that genetic 
variation in smoking metabolism genes may increase susceptibility to clubfoot.  Based on 
this reasoning, we interrogated eight candidate genes, chosen based on their involvement in 
phase 1 and 2 cigarette smoke metabolism.  Twenty-two SNPs and two null alleles in eight 
genes (CYP1A1, CYP1A2, CYP1B1, CYP2A6, EPHX1, NAT2, GSTM1 and GSTT1) were 
genotyped in a dataset composed of nonHispanic white and Hispanic multiplex and simplex 
families.  Only one SNP in CYP1A1, rs1048943, had significantly altered transmission in the 
aggregate and multiplex NHW datasets (p=0.003 and p=0.009).   Perturbation of CYP1A1 by 
rs1048943 polymorphism causes an increase in the amount of harmful, adduct forming 
metabolic intermediates.  A significant gene interaction between EPHX1 and NAT2 was also 
found (p=0.007).  This interaction may affect the metabolism of harmful metabolic 
intermediates.  Additionally, marginal interactions were found for other xenobiotic genes 
and these interactions may play a contributory role in clubfoot.  Importantly, for CYP1A2, 
significant maternal (p=0.03; RR=1.24; 95% CI: 1.04-1.44) and fetal (p=0.01; RR=1.33; 
95% CI: 1.13-1.54) genotypic effects were identified, suggesting that both maternal and fetal 
genotypes impact normal limb development.  No association was found for maternal 
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smoking status and tobacco metabolism genes.  Together, these results suggest that 
xenobiotic metabolism genes may play a contributory role in the etiology of clubfoot 
regardless of maternal smoking status and may impact foot development through 
perturbation of tobacco metabolic pathways. 
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INTRODUCTION 
 
Idiopathic talipes equinovarus, or isolated (non-syndromic) clubfoot is a common 
birth defect that has been recognized and described for centuries.  All over the world, since 
the time of the earliest forms of language and writing, clubfoot has been etched, painted and 
written into human history.  The clubfoot deformity can be seen in the tombs of the ancient 
Egyptians (1). Archeologic evidence shows that the ancient Aztec tribes in Mexico 
recognized clubfoot as a deformity and treated it with splints (1).  In what is today the 
European continent, Hippocrates scribed one of the first formal descriptions of clubfoot as 
early as 300 BC (1).  From the tenth century, clubfoot is mentioned in an Indian prayer book 
by Yajur-Veda (2).   
Throughout the Middle Ages, clubfoot was considered a punishment from God for 
mothers who had lived a sinful life, or the result of a mother sitting too long with crossed 
legs (2).  Beginning in the middle of the seventeenth century, writings on clubfoot began to 
describe its etiology, pathology, and options for treatment and/or surgical intervention (1).  
In 1842, the first Danish publications on clubfoot by Eschrict reported clubfoot as a 
consequence of developmental arrest in which the normal rotation of the foot is inhibited 
(2).  During and since that time, numerous hypotheses on the etiology of clubfoot have been 
proposed and will be discussed in more detail in the following sections.  Interestingly, 
however, the true etiology, pathology and most appropriate treatment techniques have not 
yet been unanimously accepted. 
Historical review reveals that clubfoot has been a part of human life for hundreds of 
years.  Its diagnosis, description and treatment have changed as more has been learned about 
clubfoot and as technology and medical procedures have advanced.  Currently the causes of 
clubfoot are still unknown, but diagnosis and treatments for the condition have improved.  
Therefore, those affected by clubfoot continue to benefit from the ongoing research as it 
allows for continuing modification and improvement of their care. 
 
Definition of Idiopathic Talipes Equinovarus (Clubfoot) 
Clubfoot can be considered a combination of three abnormalities in foot 
development.  These abnormalities are equinus, varus and adduction of the foot and ankle.  
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Figure 1.  Infant with clubfoot 
 
CURE Clubfoot Worldwide (cureclubfoot.org) 
The severity of each deformity can 
vary among individuals and all three 
deformities interact, such that 
correction of one abnormality requires 
correction of the other two (1). In 50-
75% of cases, clubfoot is identified as 
an isolated anomaly (3, 4).  It is these 
cases, termed idiopathic talipes 
equinovarus (referred to as clubfoot for 
the duration of this paper) that are of 
interest in the current study.  
In the remaining 25-50% of cases, clubfoot is seen in conjunction with other birth 
defects or developmental abnormalities.  When clubfoot is found as part of a group of 
anomalies, it is considered to be syndromic. Defects in the hands and eyes, cleft palate, 
micrognathia, spinal cord defects, developmental delay and motor delay are the most 
commonly associated findings (1).  Syndromic clubfoot can be the result of a chromosome 
abnormality, teratologic events, or it can develop postnatally due to neurologic disorders and 
myopathies (1).  Clubfoot is seen as a feature in a variety of syndromes, such as 
arthrogryposis, nail-patella syndrome, congenital constriction bands, lead poisoning, 
diastrophic dwarfism, Gordon syndrome and Mobius syndrome (1).  Because clubfoot can 
be a feature in various syndromes that all have different etiologies, identification of 
idiopathic clubfoot is important for an accurate determination of recurrence risks, prognosis 
and treatment. 
 
 
BIRTH PREVALENCE 
 While the birth prevalence of clubfoot is often simplified to 1 affected per 1,000 live 
births, studies have shown that it can actually vary approximately 10-fold between different 
populations (Table 1).  The highest prevalence of clubfoot is 6.8 per 1,000 live births and is 
seen in Polynesian populations (5).  The lowest prevalence is 0.57 per 1,000 live births and 
is seen in oriental populations (5).  In European, Australian or American Caucasian 
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populations the birth prevalence consistently ranges from 0.73 to 1.24 per 1,000 (6-8).  The  
prevalence in populations of Hispanic descent, both US- and foreign-born, is 0.762 and 
0.759 per 1,000, respectively (6).  The African-American population has a slightly lower 
birth prevalence of clubfoot with 0.68 children affected per 1,000 births (6).  In Texas, the 
birth prevalence of clubfoot is not significantly different between Caucasians, US-born 
Hispanics and foreign-born Hispanics (6).  
 The prevalence of clubfoot also varies between the sexes.  All studies that have 
evaluated the sex ratio have found that males are affected more often than females.  The 
ratio of affected males to affected females ranges from 1.7:1 in the Maori and Polynesian 
populations in New Zealand to 2.4:1 in the South Australian population (8, 9).  Studies of 
Table 1. Compilation of clubfoot incidence, gender prevalence and laterality in various populations
Reference Population
Incidence 
per 1,000 
N M:F Laterality
Alberman, 1965
a European 3 36 1.6:1 -
Wynne-Davies, 1965 European/Caucasian 1.24 144 2.1:1 -
Hawaiians 6.8 - - -
Caucasian 1.12 - - -
Unmixed Orientals 0.567 - - -
Caucasian - 120
B = 49%;                           
U = 57% R and 43% L
Polynesian - 118
B = 41%;                           
U = 54% R and 46% L
Chapman, 2000
Polynesian (Maori 
or New Zealand)
- - 1.7:1
U = 61.3% R and 38.7% 
L
Caucasian 0.725 255
Black 0.683 67
Foreign-born Hisp 0.759 159
US-born Hisp 0.762 177
Overall 0.740 1354
Byron-Scott, 2005 South Australian 1.1 231 2.4:1
B = 45%;                           
U = 58% R and 42% L
Cardy, 2007 UK - 194 2.1:1
B = 50%;                           
U = 57% R and 43% L
a
Other defects seen in 33%; 13.3% had a sib with severe malformations
b
Found POR to be similar in all groups
Ching, 1969
Moorthi, 2005
b
B = 49.3%;                        
U = 56.6% R and 43.4% 
L
2:1
2.2:1Cartlidge, 1984
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European Caucasian populations of European descent have consistently found a 2:1 male to 
female ratio (6, 7, 10, 11).   
 Clubfoot can be bilateral or unilateral, with either the right or the left foot affected 
(Table 1).  Bilateral clubfoot occurs in 41% to 57% of cases (6, 8-11).  When the clubfoot 
deformity is unilateral there seems to be a slight predominance of right-sided cases (54-
61%) versus left-sided cases (39-46%) (6, 8-11).  The variation in the data for laterality is 
likely due to the ascertainment methods used for each study and differences among the 
populations studied.  In general, approximately half of all clubfoot cases are unilateral, with 
the right foot affected more often than the left foot. 
 
 
LIMB DEVELOPMENT 
 It is important to examine and understand normal limb development so that it can be 
compared to the aberrant limb development seen in clubfoot (Figure 2).  Because the 
clubfoot has all of the same components as a normal foot, observations of when the 
development between the clubfoot and normal foot diverge are of particular importance to 
understanding its etiology.  By identifying differences during development, researchers can 
better identify when a change in development occurs, what may be causing the deformity, 
and how it might be prevented or better treated.  
 
Normal Limb Development 
 The development of the lower limb as a unique and identifiable part of the human 
body begins in the embryonic period of morphogenesis, after fertilization, cleavage, 
gastrulation and neurulation have all been completed (12, 13).  The formation of the limbs is 
a result of cell proliferation, cell differentiation and patterning (12).  The process begins 28 
days after fertilization, at which time the limb bud only consists of loose mesenchymal 
tissue surrounded by epithelial ectoderm (13).  The lower limb bud erupts opposite the five 
lumbar and first sacral somites and lengthens at the progress zone (PZ) (14).  The 
undifferentiated and proliferative state of the PZ is maintained by the apical ectodermal 
ridge (AER) (14).   
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 The cells that make up the 
lower limb are patterned into three 
axes: anteroposterior (great toe to 
fifth digit), dorsoventral (top of foot 
to bottom of foot) and proximal-
distal (ankle to toe) (13).  Various 
cell groups and numerous 
developmental genes are responsible 
for interacting and coordinating this 
pattern through inhibition and 
activation at different times during 
development (13).  For example, 
mesenchymal cells within the zone 
of polarizing activity (ZPA) are 
responsible for producing diffusible 
morphogens that polarize the cells 
along the limb based on a 
concentration gradient (14). 
 As development progresses, 
the homogeneous mesenchymal 
tissue differentiates.  The center of 
the limb bud forms a chondrogenic core that is surrounded by dense vasculature.  This 
process occurs in a proximal to distal pattern and represents the beginning of the formation 
of the skeleton in the leg.  In the eighth week all of the future skeletal components of the leg, 
except the distal phalanges, exist but are made of cartilage, and apoptosis occurs which 
allows for separation of individual digits.  Amongst the cartilage and dense vascular beds, 
nerves begin to grow into the lower limb and muscle tissue develops.  From the end of the 
embryonic period to just before birth, the cartilage skeletal structures ossify to form bone 
(13).  
 The mechanism for vasculature development in the limbs is less well described.  
Initially there are multiple arteries that innervate the lower limb (13).  The arteries form one 
Figure 2. Illustrations of embryonic development of the 
limbs (32-56 days) 
 
This figure was published in The Developing Human, 8
th
 
ed., Moore & Persaud, The Limbs, 367, Copyright Elsevier 
(2008). 
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single axial artery that comes from the umbilical artery and becomes the gluteal, sciatic, 
proximal politeal and distal peroneal arteries (13).  Further artery formation occurs 
secondary to axial artery formation (13).  The adult vasculature pattern is achieved by the 
eighth week (14).   
 The mesenchymal cells that will become the leg muscles migrate and surround the 
chondrogenic core of the limb bud in the fifth week (12).  In a proximal to distal pattern the 
mass of cells develop into individual muscles until the eighth week, when most of the adult 
muscles are formed and fetal movement can begin (13).  During this time the cells undergo 
differentiation and interact with other cells to form myoblasts, myotubes, sarcomeres and 
myofibrils (13).  Most muscle cells are developed prior to birth and all are formed within the 
first year of life (13). 
 As the tissues in the lower limbs differentiate and the limb bud grows along all its 
axes, it also begins to rotate (Figure 3).   In fact, early in development a fetus sits with its 
lower limbs in a clubfoot position (2).  Before the seventh week the preaxial border sits 
cranially and the postaxial border sits caudally (12).  In the seventh week the leg extends 
ventrally and then the lower limbs rotate medially 90° (12).  In the eighth week of 
development the feet display plantar flexion with adduction of both the forefoot and midfoot 
(2).  In the beginning of the third month there is plantar flexion, adduction and supination 
which slowly resolves until the fourth month when only adduction of the forefoot and 
supination persist (2).  By the twelfth week of gestation the embryo is fully formed and will 
grow and mature for the remaining time in the womb.  The gross morphology of the lower 
limb has been summarized by Boehm into 4 stages: 
1. I (eight weeks): The foot is 90° equinus and adducted. 
2. II (nine to ten weeks):  The foot is 90° equinus, adducted and supinated. 
3. III (ten to eleven weeks):  The foot dorsiflexes at the ankle.  Mild equinus and 
significant supination persist.  The first metatarsal retains adduction. 
4. IV (twelve weeks): The foot pronates to a position of midsupination (will not be 
completed until after birth) and equinus positioning is resolved (14).   
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 Limb development is a complex process and perturbation of any aspect could 
potentially result in anomalous development and malformations.  Consequently, there have 
been numerous hypotheses proposed regarding the etiology of clubfoot.  Many of these 
hypotheses are based on comparisons between the anatomy and development of the clubfoot 
and the normal foot.  To make this comparison, one must also be familiar with the functional 
and structural differences in the clubfoot. 
 
Clubfoot Anatomy and Development 
 Interestingly, all normal elements of the foot are present in the clubfoot deformity 
(2).  It is the relative position, size and shape of the bones, as well as contractures and 
hypoplasia of various muscles, ligaments and joints that comprise the deformity (1, 2).  It is 
still unclear precisely which abnormalities are primary defects and which may be secondary 
malformations (1, 2).  However, it is known that the clubfoot deformity is comprised of 
abnormal equinus, varus and adduction of the ankle and foot, which can frequently be 
associated with a cavus deformity.  The equinus deformity refers to the plantar-flexed 
positioning of the foot, which is due to ankle joint equinus, inversion of the 
talocalcaneonavicular complex and plantar flexion of the forefoot.  The varus deformity 
describes the inward rotation of the hindfoot, primarily at the talocalcaneonavicular joint.  
Adduction is a consequence of the medial displacement of the talonavicular and anterior 
Figure 3.  Illustrations of positional changes of the developing limbs of human embryos 
 
A. 48 days;  B. 51 days;  C. 54 days;  D. 56 days.  
This figure was published in The Developing Human, 8
th
 ed., Moore & Persaud, The Limbs, 367, 
Copyright Elsevier (2008). 
8 
 
subtalar joint which causes the foot to turn inward.  The cavus component refers directly to 
the forefoot plantar flexion that can accompany the other three deformities (1). 
 The severity of clubfoot differs among individuals and these findings are variable, 
meaning they are not all seen in all cases (1, 2).  The severity of the clubfoot deformity may, 
therefore, be attributed to the degree of the displacement and malformation of the bony 
structures, while resistance to corrections is often a consequence of the changes and rigidity 
in the soft tissues (1). With a better understanding of the normal and abnormal structures of 
the foot, methods for treatment have been theorized, implemented and refined over the last 
century. 
 
 
TREATMENT AND PROGNOSIS 
All treatments of clubfoot seek to correct both the displacement of the bones and the 
function of the soft tissues in order to return the ankle and foot to its normal positioning. The 
goal is to give the patient a “functional, pain-free, normal-looking, plantigrade foot with 
good mobility, without calluses and requiring no modified shoes” (Ponseti, 1996).  “A 
totally normal foot is not attainable” (Ponseti, 1996).  There are multiple methods and 
procedures in place, which involve serial manipulations, castings and bracing, with 40% of 
patients requiring more invasive, surgical intervention (3, 15).  Ideally, treatment begins 
soon after birth (2, 16).  Depending on the severity of the clubfoot and tendency for relapse, 
correction could continue through a child’s fourth year of life (16).  Therefore, correction of 
clubfoot can be physically, emotionally and financially overwhelming for an individual and 
their family members. 
 
Non-surgical Treatment 
Almost all orthopedic practitioners believe that initial treatment of clubfoot should 
be non-surgical (1, 2, 17).  Non-surgical methods utilize manipulation of the limb to stretch 
the soft tissues, muscles, tendons, ligaments and joint capsules (2).  Short-term, or daily 
manipulations use bandages or splints while longer-term manipulation requires plaster 
casting (2) (Figure 4).  The most common form of non-surgical correction is serial casting, 
which can be accomplished via multiple methods (17).   
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In 1939, Kite proposed a method 
of casting that sought to correct each 
component of the clubfoot deformity 
separately, in a sequential procedure (16).  
Kite’s casting method lasted up to 2 years 
in some cases and 50-75% of cases still 
required subsequent soft tissue release 
surgery for complete correction (16).   
In the 1940’s, in response to the 
onset of painful outcomes resulting from treatment with surgical techniques, Ignacio Ponseti 
modified the previous casting method to include serial manipulation, casting, tenotomy of 
the Achilles tendon and bracing (16, 17).  The Ponseti method avoids bone and joint surgery 
by beginning treatment with gentle manipulations and plaster casting followed by splinting 
for up to 4 years to prevent relapses (18).  This method boasts nearly a 90% success rate 
after an average treatment time of 49 months (8.6 weeks of casting) with 70-90% of 
individuals undergoing an Achilles tenotomy and approximately 50% requiring anterior 
tibial tendon transfers (16-18).  Relapses are rare after a child turns 5-years-old and 
extremely rare after 7-years (18).   
Ideally an individual would begin casting approximately 24-hours after birth and 
have their casts changed every few days for a duration of 6-8 weeks (2).  Castings are often 
continued beyond 8-weeks as long as improvement is detected (1).  However, if evaluation 
at approximately 2-3 months reveals that the foot is not completely corrected, it is unlikely 
that it will respond to further casting or other non-operative techniques (1).  Although safer 
than surgery, non-operative techniques are generally only successful in 15-50% (17).  There 
is also an increased risk for pressure sores, fractures and abnormal structural changes, such 
as rocker-bottom feet (17).    
 
Surgical Treatment 
The goal of surgery for the correction of clubfoot is to reestablish normal 
relationships between the bones of the foot and ankle and balance the correction of the 
surrounding soft tissue to prevent relapse (17).  Surgical treatment of clubfoot can include 
Figure 4.  Clubfoot casting
CURE Clubfoot Worldwide (cureclubfoot.org) 
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soft-tissue release, tendon transfers and bony operations (1).  Surgical options for clubfoot 
correction became more widely available in the 1800’s, when anesthesia and aseptic 
techniques were introduced (16).  Soft-tissue releases were the most common surgical 
procedures performed and resulted in good outcomes in 45% of cases (16).  Soft-tissue 
release operations were promoted between the 1970’s and 1990’s, but some studies have 
shown short- and long-term consequences associated with this type of correction (16).  
Complications such as overcorrection, neurovascular injuries, joint stiffness, arthritis, 
muscle weakness, pain and residual deformity have been reported in a series of studies (16, 
17).  To minimize the risks of surgery, surgeons tend to postpone surgery until an infant is 6 
to 12-months of age because the foot is bigger and easier to operate on, and it decreases the 
risk imposed by anesthesia (17).   
Unfortunately, most cases (89.2%) of clubfoot require some type of corrective 
surgery (8).  In a review of 200 unselected clubfeet, Dangelmajor (1961) found that 60% of 
cases required soft tissue or bony surgery and that each foot had an average of 2.7 operations 
(1).  The study also found that the active treatment time for patients who underwent surgery 
was 8 4/12 years, with 45% of individuals attaining a good outcome (1).  Today invasive 
surgery is recommended only after serial manipulation and casting techniques have been 
attempted and have failed, or have produced inadequate results; although failure of 
correction has not been adequately described (16, 17). 
 
Prognosis 
Isolated clubfoot is not lethal; however, there are varying degrees of severity that can 
drastically affect an individual’s prognosis and, ultimately, quality-of-life (8).  In general, 
the more severe the deformity the more difficult it is to correct (1).  Milder cases tend to 
correct within 2-3 months and are less likely to relapse (1).  In one study, 35% of cases were 
corrected with non-operative techniques with no relapse at the 7-year follow-up (1).  
Bilateral cases tend to be more severe and harder to correct than unilateral cases (2, 4, 11).  
Studies have found that up to 35% of bilateral cases require multiple operations while only 
22.6% of unilateral cases require multiple operations for satisfactory correction (8).  In 
contrast, Canto et al., 2008, reported that bilateral cases do not have a worse prognosis than 
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unilateral cases.  It is likely that this difference in observations is caused by a difference in 
description and classification of severity and prognosis. 
In a population of patients treated specifically by the Ponseti method 55/104 (53%) 
of feet had no relapse and 54% of patients reported their results as excellent (18).  Of the 
patients who relapsed, 25/104 (24.0%), 10/104 (9.6%) and 3/104 (2.9%) had a second, third 
and fourth relapse, respectively (18).  Of the individuals who did not rate their results as 
excellent, 20% rated them as good, 14% as fair and 12% as poor (18).  In a subsequent study 
consisting of 70 individuals, 59% of patients said that their corrected clubfoot was never 
painful and 72% had no limitation of activity (18).   
 It has been suggested that other factors, such as the time of initiation of treatment, 
the skill of the treating physician, the nature of the treatment, the duration and intensity of 
treatment and the cooperation of the parents, can also influence the prognosis (2).  For 
example, when treatment is started after 2-months of age, there is an increase in poor 
outcomes (2).  Of note, there has been no correlation found between family history of 
idiopathic clubfoot and severity of the clubfoot (11).  However, one study found that 38.5% 
of cases with a poor result at follow-up had a family history of clubfoot while only 19.4% of 
cases had a family history in the whole series (2, 11).  Therefore, the relationship between a 
family history of clubfoot and the severity, or worse prognosis, is still unclear. 
 
 
ETIOLOGY AND RISK FACTORS FOR CLUBFOOT 
 Although clubfoot is a common and well-studied birth defect, its cause(s) and risk 
factors have not yet been identified.  Many etiologies of nonsyndromic clubfoot have been 
hypothesized and include vascular obstruction, abnormal muscle development, intrauterine 
growth restriction and neurological abnormalities (1, 2, 19, 20).  Maternal factors such as 
age, education and parity have also been considered, but have not consistently been shown 
to be associated with clubfoot (6, 8, 21, 22).  In addition, segregation analyses and twin 
studies have pointed to a genetic etiology (6, 9, 23, 24).  
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Hypothesized Etiologies 
While there are many theories about the causes of clubfoot, these theories can be 
divided into a few main hypotheses.  These hypotheses are based on various studies and 
seek to explain the occurrence of clubfoot in all populations. 
 The oldest hypothesis is that there are mechanical forces that act on the developing 
fetus in the womb and cause deformity of the foot and ankle (2, 25).  These forces can be a 
result of compression by the uterus, oligohydramnios, twin gestations, restriction caused by 
the umbilical cord or amniotic bands (2).  A mechanical etiology was presented by 
Hippocrates and has not been definitively disproven to date (2).  In fact, mechanical factors 
may be responsible for some cases of clubfoot, but are rare and cannot explain the majority 
of cases (2).   
 A second hypothesis is that there is arrest in fetal development that inhibits the 
normal rotation of the lower limb (1, 2).  This hypothesis stems from the findings from 
Eschricht (1842) and Bohm (1929) that the feet are in a clubfoot-like position in normal 
development and rotate toward pronation later in development (2).  The cause of the 
developmental arrest has not yet been determined, but the mechanism is considered to act 
similarly to teratogenic effects, which are affected by individual susceptibility, timing and 
duration of the event (1).   
 There have also been suggestions that malformed muscles, tendons, and bones are 
responsible for the development of the clubfoot phenotype (2). One study suggests that there 
is a relationship between clubfoot and embryonic arterial accidents (19).  In contrast to these 
hypotheses, studies looking at the structural malformations of the clubfoot, such as muscular 
imbalances, have found a range of abnormalities that lack a consistent pattern or 
presentation (2, 21).   
 Finally, it is hypothesized that clubfoot is genetic and can be inherited within 
families through genes.  Support for this theory comes from a higher prevalence among 
relatives of those affected than in the general population, increased concordance among 
monozygotic twins compared to dizygotic twins and numerous segregation analyses (2).  
The evidence for a genetic component to the development of idiopathic clubfoot is discussed 
in more detail in the following paragraphs. 
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Evidence for a Genetic Etiology  
 One piece of evidence supporting the involvement of genetic factors in the 
development of clubfoot comes from twin studies.  By analyzing concordance between twin 
pairs, two twin studies in Caucasian populations both found that genes likely play a role in 
clubfoot development (23, 26).  Idelberger (1939) studied 40 monozygotic twin pairs and 
143 dizygotic twin pairs and found 32.5% concordance among the monozygotic twins and 
2.9% concordance among the dizygotic twins (23).  Therefore, if one child in a monozygotic 
twin pair has clubfoot, there is a 33% risk for the second twin to also have clubfoot (23).  In 
dizygotic pairs, the risk is approximately 3% (23).  These results were mirrored by a study 
performed in a Danish population of 12 monozygotic twins, 22 dizygotic twins of the same 
sex and 18 dizygotic twins of opposite sex (26).  Pairwise concordance for monozygotic 
twins was 0.17 (95% CI: 0.02-0.48), giving a recurrence risk of approximately 17% (26).  
Pairwise concordance for dizygotic twins of the same sex was 0.09 (95% CI: 0.01-0.32) and 
for all dizygotic twins was 0.05 (95% CI: 0.006-0.18), giving a recurrence risk of 
approximately 9.1% and 5%, respectively (26). 
 There are many studies that have described the likely pattern of inheritance for 
Table 2. Proposed inheritance patterns for clubfoot 
Reference   Findings 
Wynne-Davies, 1965   Multifactorial 
Reimann, 1967   Irregular dominant/low penetrance or polymeric 
Wang et al., 1988 
  
One major gene with additional contribution of 
multifactorial inheritance 
Rebbeck et al., 1993 
  
Single gene, Mendelian inheritance, two alleles, 
incomplete dominance, with unmeasured factors 
shared among siblings 
Lochmiller et al., 1998   Major locus additive model 
Andrade et al., 1998 
  
Recessive mixed gender-specific model with 
reduced penetrance/major autosomal locus with 
additional polygenic component 
Chapman et al., 2000   Single dominant gene with reduced penetrance 
Engell et al., 2006 
  
Genetic component with predominant nongenetic 
factors 
Kruse et al., 2008   Multifactorial threshold model 
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clubfoot (Table 2).  It is unlikely that the inheritance is solely autosomal dominant or 
autosomal recessive because there are affected children who do not have affected parents, 
and the prevalence of the deformity is the same among parents, siblings and children of 
probands (2).  It is also unlikely that the inheritance is X-linked, either recessive or 
dominant, because there is transmission from father to son (2).  This is, in fact, precisely 
what segregation analyses have concluded.  By analyzing affected individuals and their 
pedigrees, researchers have found that a mixed model, involving multiple genes and other 
factors, best describes the segregation patterns seen in the families studied (7, 24, 26-30). 
 Pedigree analysis has also elucidated the prevalence and recurrence risks of clubfoot 
in families with an affected relative.  In 1984, Cartlidge reported a positive family history in 
54% and 30% of probands in the Polynesian and Caucasian populations, respectively.  This 
is higher than other reports for Caucasian families, which find that 24% of cases had a first-, 
second- or third-degree relative with clubfoot (10, 30).  In European Caucasian populations, 
2.14% to 2.9% of affected individuals also had an affected first-degree relative, giving 
clubfoot a recurrence risk of 17 to 20 times higher than the risk for the general population 
(21, 23).  This risk decreases when individuals are more distantly related (7, 10, 30).  
Second-degree relatives have a risk six times higher than the population risk while third-
degree relatives have a risk close to the general population (23).  In general, the risk of 
recurrence for siblings is approximately 3%; 2% for siblings of affected males and 5% for 
siblings of affected (31). 
Many studies have found that the risk for clubfoot is increased further for males 
when they have an affected female relative (2, 21, 28).  This finding may be explained by 
the Carter effect.  The Carter effect describes a phenomenon in which one sex requires a 
greater genetic contribution in order to develop a condition (28).  This can be seen in 
families if there is a discrepancy in the susceptibility to a condition and a tendency for one 
sex to transmit the disorder more frequently than the other (28).  This effect is seen for 
clubfoot, as 59% of children born to mothers with clubfoot versus 37% of children born to 
fathers with clubfoot are also born with clubfoot (28).  Females are 5.6 times more likely 
than males to transmit clubfoot to their children (28).  The lowest prevalence of clubfoot is 
in daughters of men with clubfoot while the highest prevalence is in sons of females with 
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clubfoot (28).  The Carter effect supports a multifactorial threshold model of inheritance, for 
which females require a greater genetic load to be affected (28).  
 
Environmental Risk Factors 
 Numerous environmental risk factors have been evaluated for a relationship with the 
development of clubfoot.  A study using birth certificates and birth defect registry 
information for 134 children with isolated clubfoot found male gender, death of a preterm 
sibling and being married were independently related to clubfoot (22).  This was the first 
report of a relation of death of a preterm sibling and being married with clubfoot (22).  The 
increased risk for males is consistent with the predominance of male cases and a 
multifactorial model (28).  The study authors suggest that the relationship between clubfoot 
and marital status may be the result of a diagnostic bias, while the relationship with death of 
a preterm sibling may stem from overreporting by case mothers and underreporting by 
control mothers (22).  No significant associations were found for other parameters, such as 
low parity, seasonality, young maternal age and breech prenatal position (22).  Additionally, 
this study did not offer support for the intrauterine constraint theory (22). 
 Other studies have also found a lack of association between various environmental 
factors and clubfoot.  A study with 285 cases of idiopathic clubfoot by Lochmiller, et al. 
(1997) found no support for variation in prevalence of clubfoot based on months/season, 
maternal gravidity, amniotic levels during pregnancy or breech presentation (30).  Wynne-
Davies (1965) found no association between parental age nor birth order.  
 Early amniocentesis is a procedural risk factor that has inconsistently been shown to 
increase the risk of clubfoot (32-34).  The CEMAT group found that the incidence of 
clubfoot is significantly increased (p=0.0001) from 0.1% in the midtrimester amniocentesis 
group to 1.3% in the group that underwent early amniocentesis (before 13-weeks gestational 
age) (32).  They also found that there was a significant increase in amniotic-fluid leakage in 
women who underwent early amniocentesis versus those who had midtrimester 
amniocentesis (p=0.0007) (32).  When they examined what week of pregnancy the cases had 
undergone amniocentesis, they found that the highest incidence of clubfoot (2.1%) was seen 
when amniocentesis was performed in the 12
th
 week of pregnancy (32).  Their conclusions 
were that early amniocentesis, when performed between 11 weeks + 0 days and 12 weeks + 
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6 days, is associated with an increased risk of clubfoot (32).  This was true whether or not a 
woman experienced amniotic-fluid leakage, however, if a woman experienced leakage the 
incidence of clubfoot was found to be as high as 15% (32).  Similar incidences have been 
reported by two subsequent studies that have compared the risks of chorionic villus 
sampling (CVS) to early amniocentesis (35, 36).   
Maternal smoking is the only single environmental risk factor shown to be 
significantly associated with clubfoot and was first suggested by Alderman et al. in 1991 
(22).  This study found an OR of 2.22 (95% CI: 0.7-6.4) for mothers who smoked 1-10 
cigarettes per day and an OR of 2.90 (95% CI: 0.8-9.2; p-value for trend=0.3) for mothers 
who smoked greater than 10 cigarettes per day (22). Therefore, a greater exposure to 
cigarette smokes increases the association between smoking and clubfoot.  The association 
between smoking and clubfoot is also stronger for affected females, OR = 2.28 (95% CI 
0.68-7.66), compared to affected males, OR = 1.16 (95% CI 0.53 – 2.55) (10).  Because 
females are the less frequently affected sex and, theoretically, require a greater genetic and 
environmental load, this finding is consistent with the Carter Effect and the findings by 
Kruse et. al., 2008.   
 
Honein et al. (2000) evaluated smoking and family history of clubfoot in a cohort of 
346 infants from the Atlanta Birth Defects Case-Control Study (ABDCCS) and 3,029 infants 
without birth defects.  The study found that both maternal smoking and family history, 
individually, are associated with an increased prevalence of clubfoot with an OR of 1.34 
(95% CI: 1.04-1.72) and 6.52 (95% CI: 2.95-14.41), respectively (Table 3) (37).  
Furthermore, a history of maternal smoking and a family history of clubfoot resulted in an 
OR of 20.3 (95% CI: 7.90-52.17) (37).  
In 2002, Skelly, et al. confirmed that there is a strong association between maternal 
smoking and clubfoot by analyzing 239 cases of clubfoot and 365 controls in Washington 
State.  The study found that the risk of clubfoot for mothers who smoked at any time during 
Table 3. Risk of clubfoot by smoking and family history*
Risk Factors OR (95% CI)
Smoking 1.34 (95% CI: 1.04-1.72)
Family History 6.52 (95% CI: 2.95-14.41)
Smoking + Family History 20.3 (95% CI: 7.90-52.17) 
* Created from Honein, et al., 2000
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pregnancy was 2.2 times that of controls (95% CI: 1.5-3.3) (38).  In addition, the risk was 
correlated with the number of cigarettes smoked per day, resulting in a 3.9-fold (95% CI: 
1.6-9.15) risk for women who smoked 20 or more cigarettes a day (38).   
Lastly, in 2008, Dickinson, et al., supported the hypothesis that maternal smoking is 
associated with an increased risk of clubfoot with an OR of 1.79 (95% CI: 1.17-2.74) (39).  
This study also found a stronger association between maternal smoking and female fetuses 
versus male fetuses, but did not support a dose dependent association in any dataset (39).   
Together these results imply an increased risk of clubfoot for children of mothers 
who smoke during pregnancy (Table 4).  The risk for clubfoot is increased further for 
children of mothers who smoke during pregnancy and have a positive family history, 
supporting an etiology with environmental and genetic interactions. 
 
 
 
 
 
 
 
 
 
FINDING DISEASE-SUSCEPTIBILITY GENES IN MULTIFACTORIAL TRAITS 
 Finding genes responsible for susceptibility to multifactorial diseases is important 
because identification of causative factors can provide information about the 
pathophysiology of the disease, increase the understanding of human development and 
biology, improve diagnosis and help identify improved therapies (40).  Multifactorial 
inheritance, by definition, involves the complex interaction of multiple genes and 
environmental factors.  Therefore, many of the methods used to identify genes responsible 
for disorders with simple Mendelian inheritance are not as useful for common, more 
complex disorders.  The methods for identifying disease genes range from positional cloning 
to genome-wide association studies (GWAS) and utilize different statistical methods and 
Table 4. Odds ratio for clubfoot in mothers who smoke during pregnancy
Study
Cases of 
Clubfoot
Smoking OR (95% CI)
Alderman, et al., 1991 175 2.6 (95% CI: 1.6-4.0)
Honein, et al., 2000 346 1.34 (95% CI: 1.04-1.72)
Skelly, et al., 2002 239 2.2 (95% CI: 1.5-3.3) 
Dickinson, et al., 2008 443 1.49 (95% CI: 1.15-1.92)  
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technologies (41-43).  However, all methods are based on the principles of genomic 
structure and segregation. 
 
Genetic Markers and Variation 
 The genome contains infinite variability within a population.  This variation is 
created by changes in the coding regions of genes, as well as intragenic and intergenic 
sequences that makes up the genetic code (44).   When these variants are present in at least 
1% of the population, they are considered normal variants or polymorphisms.  Researchers 
can identify and analyze the inheritance of unique variations within an individual’s genome 
to look for genes that may play a role in a genetic susceptibility to a disease, condition or 
trait.  Over the years, many different types of genetic markers have been identified and 
utilized for scientific research (45).  Restriction fragment length polymorphisms (RFLP), 
variable number of tandem repeats (VNTR or minisatellites) and short tandem repeats 
(STRP or microsatellites) became widely used in the 1980’s (45).  These markers consist of 
variable lengths of DNA sequence that can be detected through polymerase chain reaction 
(PCR).  There are a few thousand VNTRs in the human genome, while there are >100,000 
microsatellites that cover the majority of the genome (45).  Microsatellites tend to be highly 
heterozygous and amenable to analysis using high throughput technology (45).   
At the beginning of the twenty-first century, single nucleotide polymorphisms 
(SNPs) became widely used and were found to be the most prevalent type of variation in the 
genome, occurring every 300 base pairs (45).  Today, more than three million SNPs have 
been described (45).  These markers are useful tools for identifying genetic variants that can 
affect susceptibility to a disease in a population (45).  SNPs are found in coding and non-
coding regions within genes and between genes and can be used in linkage and association 
analyses (46).  They can be causative or indicative of a disease based on their interaction or 
effect on gene function or regulation (46). Identification of SNPs, improvements in high 
through-put technology and reduction in costs and labor have allowed for genome-wide 
association studies (GWAS) which can analyzed an entire genome for association with a 
disease susceptibility or trait (45).   
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Heritability 
Past and present methods of evaluating a genetic etiology of a condition or disease 
trait have started by establishing the heritability of a condition (41, 43).  Heritability 
measures how much of the phenotypic variation in a condition is caused by genetic variation 
(41).  Heritability can be established through twin studies and segregation analyses (41).  
Twin studies are based on the premise that monozygotic twins share 100% of their genes 
while dizygotic twins share 50% of their genes, like non-twin siblings.  Both monozygotic 
and dizygotic twins share an environment during fetal development.  Therefore, if a trait has 
a genetic component, and is not purely the result of environmental factors, there should be a 
greater concordance between monozygotic twins when compared to dizygotic twins (41).  
Segregation analysis seeks to characterize genes with a major role in pathogenesis by 
proposing a mode of inheritance and genetic parameters and determining the model that best 
fits the segregation patterns within a family or group of families (41).  By studying twins 
and families with a condition or disease trait, information about whether or not a condition is 
genetic and how that condition is most likely inherited (autosomal dominant, autosomal 
recessive, X-linked recessive, multifactorial, etc.) can be deduced.  Once the etiology of a 
trait is determined to have a genetic component, more analyses can be undertaken to identify 
which genes are responsible for pathogenesis. 
 
Linkage and Association 
Linkage analysis is one approach to localize a disease susceptibility gene by 
narrowing the chromosome region through observation of recombination events within 
families (41, 42).  Multiplex families are required for linkage analysis.  The result of a 
linkage analysis is translated into a physical genetic distance, which can be used to create a 
genome-wide genetic linkage map for identification of susceptibility genes at multiple loci 
(41).  Linkage analysis is useful when the gene of interest is unknown.  This method is 
underpowered when there are many low penetrant genes involved and resolution is hindered 
if there are few generations within the families being studied (41, 42).   
Association analysis is a second approach, which utilizes linkage disequilibrium 
(LD) to identify a marker in close proximity to a disease susceptibility allele (43). A marker 
is in LD with a disease allele when there is a small probability of crossover between the two 
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loci, which means the marker and the allele may be close together on a chromosome (43).  
Association studies use case-control, simplex or extended families.  This method is 
generally more powerful than linkage analysis and offers a more narrow genomic interval 
within which the gene of interest may be contained (42).  
 
Gene Discovery 
The traditional route used to identify causative genes for Mendelian disorders has 
been positional cloning by linkage analysis (42).  This method is able to find a location of 
the gene likely causative for the phenotype within the genome when the gene is not yet 
known.  Positional cloning utilizes families with a condition of interest to perform linkage 
analyses and/or association tests to map a gene to a small interval within the genome (42, 
43).  Once an area is defined, the genes within the interval can be evaluated to determine if 
their biological function has relevance to the observed trait (42).  Researchers can then look 
at the most probable genes and scan for disease-causing mutations (42).   
Positional cloning has had only limited success for multifactorial disease because of 
the weak relationship between any one locus and the observed phenotype (42).  Linkage 
analysis, population-based association studies, and chromosomal deletions, duplications or 
rearrangements can help identify a genomic region of interest, but often the interval is large 
and contains many hundreds of genes (42).  Therefore, most research on complex disease 
susceptibility has focused on testing plausible candidate genes through linkage and 
association approaches (41, 42).  This method requires knowledge about the biology of 
complex disease and the function of candidate genes in an organism. 
The candidate gene approach uses information about the biology of the disease, 
including biochemical pathways, tissue expression profiles, differential expression studies 
and animal models to identify genes with a likely involvement in the susceptibility to the 
disease state (42). Once identified, the genes can be prioritized for the ones most likely to 
play a significant role in pathogenicity (42).  The segregation patterns of polymorphic 
markers in flanking high-priority candidate genes can be analyzed to look for disease-
associated variation (42).  
 Using the candidate gene approach, studies have begun to examine whether there is 
an association between SNP variants in and around genes and SNP haplotypes with 
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clubfoot.  Genes involved in limb development and apoptosis have been examined and 
appear to play a modest role in the etiology of clubfoot (47-49).  Few studies have been 
performed on smoking metabolism genes (J. T. Hecht, et al., 2007).  Based on the consistent 
association between smoking and clubfoot and the previous NAT2 association with clubfoot, 
a systematic interrogation of smoking metabolism genes is needed.   
 
 
SMOKING METABOLISM 
 
Xenobiotic metabolism of cigarette smoke and PAH adduct formation 
 Metabolism of the components of cigarette smoke is accomplished through the 
xenobiotic metabolism pathway (Figure 5) (50).  The pathway involves biotransformation of 
a lipid-soluble xenobiotic compound by functionalization and/or conjugation reactions into 
polar, water-soluble metabolites that can be excreted (50, 51).  This pathway consists of two 
phases, which are denoted phase I and phase II.  Phase I is characterized by the 
functionalization reactions and utilizes enzymes capable of dehydrogenation/hydrogenation, 
oxidation, hydrolysis, reduction and mono-oxygenation (50).  Phase II consists of the 
conjugation reactions and utilizes enzymes capable of glucuronidation, sulphation, 
acetylation, GSH-conjugation and methylation (50).  Biotransformation can detoxify a 
compound or create a more toxic intermediate metabolite (50).  The effects of the 
Figure 5. Xenobiotic metabolism pathway
Adapted from http://en.wikipedia.org/wiki/File:Xenobiotic_metabolism.png,  
Dr. Tim Vickers 
Reactive 
Intermediates
Tobacco 
smoke
Excretable
compound
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intermediate metabolite are dictated by the type of environmental exposure (parent 
compound) and by the effectiveness/activity level of both phases of xenobiotic metabolism.  
 Cigarette smoke is one type of environmental exposure and consists of more than 
4,000 chemical compounds, including dioxins, dioxin-like compounds and other AhR 
agonists (52, 53).  The main toxins in cigarette smoke are the polycyclic aromatic 
hydrocarbons (PAHs) (53, 54).  Individuals are exposed to PAHs everyday through fossil 
fuel combustion, forest fires and car exhaust; however, the greatest exposure to PAHs comes 
from cigarette smoke (55, 56).  Metabolism of these toxins occurs primarily in the liver, 
which expresses numerous drug-metabolizing enzymes (DME) (50, 57, 58). 
PAHs from cigarette smoke, such as 
Benzo[a]pyrene (BaP) and 7,12-
dimethylbenz[a]anthracene (DMBA) form 
DNA and protein adducts (56).  PAH-DNA 
adducts and dioxins from cigarette smoke can 
cause mutagenesis and teratogenesis (52, 59).  
The mechanism for xenobiotic metabolism and 
adduct formation is specific to a unique 
compound, however, benzo(a)pyrene (BaP) 
can be used as a prototypic PAH to discuss the 
general metabolism of all lipophilic 
xenobiotics (Figure 6) (57).  Once in the body, 
BaP is initially metabolized by CYP1A1 or 
CYP1B1 to an epoxide, such as 
benzo(a)pyrene-7,8-epoxide (60, 61).  The 
compound is then hydrolyzed by the microsomal epoxide hydrolase (mEH) enzyme to a 
dihydrodiol (59).  CYP1A1 or CYP1B1 can transform the intermediate compound to a highly 
reactive diol-epoxide that can covalently bind DNA (59).  Not surprisingly, it has been 
shown that smoking appears to be associated with an increase in DNA adduct levels (59).  
Additionally, increased metabolism of PAH-diol-epoxide forms with decreased capacity to 
conjugate these reactive intermediates was associated with an increased level of adducts 
(59).  
Figure 6.  Metabolism of BaP*
*Created from text; Nock, et al., 2007 
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Regulation of CYP1 enzymes 
PAHs and dioxins also 
induce the expression of 
xenobiotic metabolism enzymes 
by binding to the aryl 
hydrocarbon receptor (AhR) 
(Figure 7) (50, 56).  The AhR is 
a transcription factor that acts as 
a xenobiotic sensor for a number 
of different hydrocarbons, 
including PAHs (56, 62). BaP 
and DMBA are two compounds 
that can diffuse across the cell 
membrane and bind to AhR as 
ligands (52, 56).  AhR-ligand 
binding causes a transformational shift, which, in turn, exposes a nuclear localization 
sequence that allows the receptor-ligand complex to enter the nucleus (56).  In the nucleus 
the complex binds the AhR nuclear translocator (Arnt), which then activates the 
transcription of cellular detoxiﬁcation enzymes (52, 56).  CYP1A1, CYP1A2 and CYP1B1 
can all be induced through the AhR cascade (52, 62, 63). 
 
Effects of Smoking During Pregnancy 
Damaging PAHs and other lipophilic substrates have been shown to cross the 
placenta and can form adducts to maternal and fetal tissues as well as in the DNA of human 
trophoblast cells (57, 64-66).  Therefore, it is important for both maternal and fetal health 
that these toxic tobacco smoke metabolites can be converted to less damaging substances 
(67).  The human placenta plays an important role in the oxidation of several xenobiotics 
(57, 66).   
Figure 7. Regulation of CYP1 enzymes 
 
Reprinted from Cancer Letters, 252 /2, Masanori Kitamura & 
Ayumi Kasai, Cigarette smoke as a trigger for the dioxin 
receptor-mediated signaling pathway, 184-194 (2007), with 
permission from Elsevier. 
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In their review of the transcriptional regulation of xenobiotic metabolism genes, 
Pavek and Dvorak (2008) highlight the role of cytochrome P450 enzymes in the placenta.  
They note that many CYP enzymes are expressed in placental trophoblast cells, but not all 
have a detectable enzymatic activity (57, 62).  The amount of CYP enzymes expressed in the 
placenta is greatest in the first-trimester, during embryogenesis and organogenesis, and 
decline throughout the second- and third-trimesters (62).  CYP1A1 is expressed and can be 
induced in placental cells throughout pregnancy while CYP1A2 expression is only detected 
in the first-trimester placenta and CYP2A6 expression has not been detected in the placenta 
at any time during pregnancy (57, 62). Basal CYP1A1 expression is inhibited during 
pregnancy by 30% in the liver and up to 60% in extrahepatic organs (66).  Interestingly, 
there is an observed increase in the concentration of AhR and Arnt within placental 
trophoblast cells (62).  This is consistent with the ability to induce CYP1A1 expression with 
exposure to cigarette smoke(57). CYP1B1, although regulated by the same cascade as 
CYP1A1, is not inducible by maternal cigarette smoking in the placenta (57). As is seen in 
maternal cells, placental CYP1A1 plays a role in the bioactivation of PAHs to reactive 
intermediates that form DNA adducts in placental and fetal tissues (62). The inductory 
mechanism for CYP1A1 is functional in the fetal liver at day 21 of pregnancy in rats (66).  
Smoking-induced elevations in CYP1A1 activity have been consistently associated with 
adverse birth outcomes, such as premature birth, IUGR and structural abnormalities (62).  
Mice exposed to PAHs had abnormal vasculature in the placenta that significantly reduced 
arterial surface area and volume of the fetal arterial vasculature (56). 
An individual’s ability to metabolize xenobiotics can be greatly affected by the 
genetic variation in their drug metabolizing genes. Numerous xenobiotic genes and variation 
within these genes have been studied.   Polymorphisms affecting the activity of CYP1A1, 
GSTM1 and GSTT1 have been shown to be detrimental to the growth and development of a 
fetus when the fetus is exposed to cigarette smoke (68-70).  Additionally, BaP has been 
shown to differentially impact the incidence of congenital malformations based on maternal 
and fetal genotype (71).  Therefore, genetic variation in xenobiotic metabolism genes may 
help explain the increase in adverse effects among some individuals. 
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Xenobiotic metabolism and genetic variation 
 An interaction between metabolism genes and cigarette smoking has been suggested 
in previous studies (68).  Consequently, the observed increased risk for clubfoot due to the 
interaction between genes and smoking may be caused by variation within the genes 
involved in smoking metabolism. 
 
Cytochrome P450 
 The cytochrome P450 (CYP450) superfamily genes are phase I mono-oxygenases 
that are anchored in the endoplasmic reticulum (50, 72).  They are key players in phase I of 
xenobiotic metabolism and can catalyze oxidation and reduction reactions (63).  Oxidation 
and reduction can convert xenobiotics to water-soluble compounds, a process known as 
detoxification, or it can increase the toxicity of a compound by creating an active metabolite 
that is a target for phase II conjugation reactions (51, 63).   
Humans have 57 cytochrome P450 genes, which are divided into 18 families and 43 
subfamilies (62).  Cytochrome P450 enzymes are labeled based on a set of standard 
nomenclature (72, 73).  The enzymes are named first by a number representing their family, 
followed by a letter representing the subfamily and, finally, a second number that identifies 
the individual enzyme (72).  Fifteen of these genes are known to play an important role in 
phase I of the metabolism of xenobiotic compounds and are from the CYP1, CYP2 and 
CYP3 families (62, 73). Smoking is an important environmental factor that influences 
CYP450 activity (63).  CYP1A1, CYP1A2 and CYP1B1 are all known to play a role in the 
metabolism of compounds found in tobacco smoke, such as polycyclic aromatic 
hydrocarbons (PAHs) and dioxins (62). CYP1A1, CYP1A2, CYP1B1 and CYP2A6 
expression has been identified in key organs, such as the placenta, liver and lungs (Table 6) 
(62).   
Variation within these genes has been identified.  In general, the most penetrant 
CYP450 genetic alterations are deletions, missense mutations and splicing defects (63).  
There have also been a few examples of mutations in the 5’- and 3’-untranslated regions 
(UTR) that affect phenotypes (63).  By looking at the variation within these key CYP450 
genes, the effects of specific polymorphisms on enzyme activity and smoking metabolism 
can be studied and hypothesized. 
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 CYP1A1 is known as one of the most important detoxification enzymes because it has 
a broad substrate specificity and wide distribution throughout the body (62).  CYP1A1 can 
be induced by cigarette smoking (74).  CYP1A1 activates and detoxifies environmental 
PAHs and aromatic and heterocyclic amines from cigarette smoke (63).  It is also known to 
produce highly carcinogenic intermediate metabolites through oxidation of PAHs (62). 
Specifically, induction of CYP1A1 catalyzes the activation of BaP to DNA-bound adducts 
(57).   
 Study of the variation in CYP1A1 has offered some insight into its role in xenobiotic 
metabolism. The CYP1A1 Ile462Val polymorphism has higher enzymatic activity (Table 7) 
(75, 76). The CYP1A1*2A allele had higher adduct levels and percent aberrant cells in the 
presence of significant environmental tobacco smoke exposure (77).    
 CYP1B1 is differentially expressed between tissues but is primarily extrahepatic, with 
the highest constitutive levels of mRNA detected in the uterus, heart, brain, lung, skeletal 
muscle and kidney (62, 63).  Like CYP1A, CYP1B isoenzymes metabolize various 
polycyclic aromatic hydrocarbons and, additionally, are involved in the metabolism of 
endogenous compounds (62).  Because of its localization within the body, CYP1B1 is not 
believed to play a major role in the overall clearance of drugs and more likely plays a critical 
role in tissue-specific metabolism of certain compounds (63).   
 Specific variants in CYP1B1 have been described (Table 7). Five common missense 
SNP mutations have been identified and form 7 haplotypes consisting of one or more of 
these SNPs (63).  One of these haplotypes, CYP1B1*7 has a significantly decreased ability 
to metabolize BaP (78).  Additionally, the 432Leu allele has a slightly higher activity in 
metabolizing BaP-7,8-dihydrodiols but slightly lower activity in metabolizing the parent 
compound, BaP when compared to CYP1B1 432Val (59). CYP1B1 polymorphisms seem to 
have an impact on DNA adduct level in populations exposed to low levels of tobacco smoke 
(77).  One allele, CYP1B1*3, seems to increase an individual’s susceptibility to DNA adduct 
formation, although it was not a significant increase (77). 
CYP1A2 is a hepatic form of CYP450s (57).  It is constitutively expressed but can be 
induced by PAHs and dioxins (62).  There have not been any common polymorphisms 
identified with functional effects and there have been only a few rare variations described 
(CYP1A2*7 and CYP1A2*11) (63). 
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 CYP2A6 is found in the liver and metabolizes a variety of tobacco-related 
precarcinogens (74, 79).  CYP2A6 is the primary human nicotine C-oxidase and is 
responsible for 70-80% of nicotine metabolism (79).  CYP2A6 is not inducible by the same 
cascade as the CYP1 family (62).  CYP2A6 is highly polymorphic but does not have 
functionally important polymorphisms in Caucasians (79).  One allele, CYP2A6*2 is 
functionally significant in Caucasians, but it is very rare (79).  One of the most important 
variant alleles is a gene deletion and is seen almost exclusively in Asian populations (79).   
Variations in P450 genes result in different rates of drug metabolism among 
individuals and several known variants produce unusual metabolites that may have harmful 
effects (51).  Therefore, variations in CYP1A1, CYP1A2, CYP1B1 or CYP2A6 may modify 
(either increase or decrease) the effect of harmful compounds found in cigarette smoke and 
their metabolites. 
 
Epoxide Hydrolase 
 Epoxide hydrolases (EH), such as EPHX1, also activate and detoxify exogenous 
compounds, including PAHs, during phase I of xenobiotic metabolism (80).  As discussed 
previously, EHs metabolize reactive epoxides to less-harmful dihydrodiol derivatives and 
can activate PAH (80, 81).  EPHX1 is the gene that encodes the microsomal epoxide 
hydrolase (mEH), which is located primarily in the endoplasmic reticulum (81). The gene, 
located on 1q42.1, is 20,271 bp and consists of 9 exons and 8 introns (81, 82).  mEH is 
constitutively expressed in diverse cell types and is found in different organs throughout the 
body (fetal liver, adrenals, kidneys, lungs, gut and placenta) (83, 84).  EPHX1 is also 
inducible and has polymorphic variants (81). 
 In 1985, researchers hypothesized that a mutation in EPHX1 could lead to an 
increase in toxic arene oxide metabolites and result in a variety of biological insults, 
including birth defects (85).  Epoxides are 3-membered strained organic configurations of 
oxygen that can cause cellular damage and genetic mutations and have been shown to 
produce birth anomalies (57, 82).  It has since been shown that certain polymorphic variants 
in EPHX1 decrease its activity by 40%, inhibiting effective biotransformation of exogenous 
compounds (81).  Currently there are 2 known polymorphisms in the coding region of the 
EPHX1 gene (80).  One polymorphism is located in exon 3 at the amino acid residue 113 
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and can be seen as a histidine or a tyrosine and the other is in exon 4 at residue 139 and can 
be a histidine or an arginine (86).  The wildtype haplotype contains a tyrosine in amino acid 
position 113 and a histidine in amino acid position 139 (113Y/139H) and has been shown to 
have an approximately 2-fold increase in activity when compared to variant forms, 
specifically in the epoxide to dihydrodiol reaction (80, 87).  
Because mEH plays an important role in the metabolism of reactive epoxides, these 
EPHX1 variants have been evaluated for association with adduct levels.  Caucasian 
individuals who are homozygous for the arginine allele at amino acid position 139 have 
been shown to have decreased levels of DNA adducts compared to wildtype (59, 77).  
Individuals heterozygous at the 139 amino acid position trended toward a significant 
decrease in adducts when the three allele combinations where compared (77).  The highest 
adduct levels were seen in individuals who were homozygous for the histidine allele at 
amino acid position 139.  Therefore, the adduct levels increase with the number of histidine 
alleles present.  Additionally, individuals homozygous for the histidine allele or 
heterozygous at position 139 who also had a tyrosine allele at position 113 have been shown 
to have significantly higher PAH-DNA adducts (59). Based on these studies, genetic 
variation in EPHX1 may contribute to the impact of an individual’s exposure to harmful 
cigarette smoke toxins and metabolic intermediates. 
 
Glutathione S-Transferase 
 Glutathione S-Transferases (GSTs) belong to a multifunctional enzymatic system 
that catalyze detoxification and activation reactions through the conjugation of biologically 
active electrophiles to endogenous tripeptide glutathione, predominantly in the liver (57, 
88).  There are 4 classes of GSTs, alpha, mu, theta and pi and all play a role in furthering the 
biotransformation of metabolites from phase I reactions (88). Of note, GSTP (pi) is the only 
GST to be purified and cloned from the human placenta and represents 85% of the GST 
activity in the placenta as early as the first trimester (57).  
2
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Table 6.  CYP450 functional alleles*
Gene Haplotype SNP ID**
Nucleotide 
change
Amino acid 
change
Phenotype
CYP1A1*2A rs4646903 3698T>C 5' near gene
Higher adduct levels and % aberrant 
cells when exposed to cigarette smoke
CYP1A1*2B
rs1048943; 
rs4646903
2454A>G; 
3698T>C
Ile462Val Increased enzymatic activity
CYP1A1*2C rs1048943 2454A>G Ile462Val Increased enzymatic activity
CYP1B1*1 WT none none Wildtype
CYP1B1*2
rs10012; 
rs1056827
142C>G; 
355G>T
Arg48Gly; 
Ala119Ser
-
CYP1B1*3 rs1056836 4326C>G Leu432Val
Decreased met of BaP, increased met 
of BaP-7,8-dihydrodiols; increased 
susceptibility to DNA adduct 
formation
CYP1B1*4 rs1800440 4390A>G Asn435Ser -
CYP1B1*5
rs10012; 
rs1056836
142C>G; 
4326C>G
Arg48Gly; 
Leu432Val
-
CYP1B1*6
rs10012; 
rs1056827; 
rs1056836
142C>G; 
355G>T; 
4326C>G
Arg48Gly; 
Ala119Ser; 
Leu432Val
-
CYP1B1*7
rs10012; 
rs1056827; 
rs1056836; 
rs4986888
142C>G; 
355G>T; 
4326C>G; 
4360C>G
Arg48Gly; 
Ala119Ser; 
Leu432Val; 
Ala443Gly
Significantly decreased ability to 
metabolize BaP
C
Y
P
1
B
1
C
Y
P
1
A
1
* Created from http://www.cypalleles.ki.se; Lamba, et al., 2002; Schwarz, et al., 2005; Georgiadis, et al., 2004; Nock, et 
al., 2007; Akilillu, et al., 2005; Rodriguez-Antona & Ingelman-Sundberg, 2006
**SNPs in this study in bold
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 The GST mu (GSTM) and GST theta (GSTT) classes have been studied because of 
their role in detoxification of activated nicotine metabolites and xenobiotics (57).  They are 
known for their involvement in the detoxification of epoxides created by the CYP450s (89).  
There are 5 sub-classes of GSTM (GSTM1-5), which cluster on chromosome 1p13 (90, 91).  
There is a large difference in the expression of GSTM between different tissue types (88).  
The most commonly expressed GSTM is GSTM1 (88).  The GSTM1 subclass is of particular 
interest because of its prominent null allele.  Only about 40-60% of individuals in the 
population express GSTM1 and, for those who do not express the gene, there is an increased 
susceptibility to DNA-adduct formation and cytogenetic damage (92-94).  GSTT has two 
sub-classes, designated GSTT1 and GSTT2 (95, 96).  These enzymes are also found in the 
liver, but have widespread expression (88).  Similarly to the GSTM1 locus, GSTT1 has a null 
allele that can be found in 10-40% of individuals, depending on the population (88). The 
null alleles for both GSTM1 and GSTT1 cause an absence of enzyme activity, and possibly 
increasing the amount of active metabolites in the body (88, 97).  Therefore, GSTM1 and 
GSTT1 activity may impact the effects of harmful intermediates created by phase I enzymes 
on a fetus (57). 
 
N-Acetyltransferase 
 N-Acetyltransferases, NAT1 and NAT2, are xenobiotic enzymes whose genes are 
located on chromosome 8p22 (http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= 
612182).  There are 20 described allelic variants in these two genes that are caused by single 
nucleotide substitutions or insertions/deletions (47, 57).  Because of their known role in 
phase II of the biotransformation of tobacco smoke, NAT1 and NAT2 were the first 
xenobiotic metabolism candidate genes considered for association analysis in clubfoot (47, 
98, 99).   
 NAT2 is of particular interest in this study because of its “slow acetylator” phenotype 
(100).  The slow acetylation phenotype is associated with a 10-20% reduction in NAT2 
protein levels and can cause an increase in harmful adduct levels (47, 100, 101).  
Approximately 40-70% of European and Northern American individuals have the “slow 
acetylator” phenotype while it is found in only 10-30% of Asian individuals (100).  Many 
functional alleles can cause the “slow acetylator” phenotype and have been shown to be 
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recessively inherited (100).  In total, there are 7 point mutations in NAT2 coding regions, 5 
of which cause amino acid changes (100).  These mutations and the associated “slow 
acetylator” alleles are presented in Tables 8 and 9.  The “slow acetylator” phenotype is 
observed in individuals who are homozygous for the G191A, C282T and T341C 
polymorphisms (102, 103).  Conversely, individuals homozygous for the A803G 
polymorphism have been classified as “rapid acetylators” (104).  There have been no 
homozygotes identified for the C418T, G590A and G857A polymorphisms (100).  Almost 
all (99%) of haplotypes in Caucasian slow acetylators share either a T341C or C282T 
polymorphism (NAT2*5 (A, B or C), NAT2*6A, NAT2*7B or NAT2*13) (100). 
  
Table 7. Acetylation activity of common NAT2 SNPs*
in vivo in vitro
rs1041983 C282T Silent (Y94) ↓ normal
rs1801280 T341C I114T ↓ ↓
rs1799929 C481T Silent (L161) unknown normal
rs1799930 G590A R197Q unknown ↓
rs1799931 G857A G286E unknown controversial
↓ = decreased N-acetylation activity level
SNP Mutation
Amino acid 
change
N-acetylation activity
 *Created from U.A. Meyer & U.M. Zanger, 1997 
T341C, C481T, A803G NAT2*5B
C282T, G590A NAT2*6A
T341C, C481T NAT2*5A
T341C, A803G NAT2*5C
C282T, G857A NAT2*7B
C282T NAT2*13
G191A NAT2*14A
Mutations
a
Table 8. Common NAT2  slow acetylator alleles*
a
Presumed inactivating mutations in bold
*Created from U.A. Meyer & U.M. Zanger, 1997
Allele Designation
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 A study by Hecht, et al. (2007) suggested that the slow-acetylator phenotype of 
NAT2 may play a role in the development of clubfoot. This is supported by the finding that 
NAT enzymes are found in the human placenta and can bioactivate certain arylamines into 
compounds that can be toxic to the fetus (57).  The study found that the T341C 
polymorphism was transmitted more often in Hispanic simplex cases (only the proband is 
affected) (47).   Additionally, the G590A normal SNP and haplotype was transmitted less 
often in the Hispanic clubfoot population (47).  These findings add support for the 
interaction between smoking metabolism genes in the lipid-soluble xenobiotic pathway and 
clubfoot.   
Together, studies have delineated the importance of CYP1A1, CYP1A2, CYP1B1, 
CYP2A6, EPHX1, GSTT1, GSTM1 and NAT2 in the metabolism of cigarette smoke. The 
genes in this study interact in the sense that they all play a role in a pathway responsible for 
metabolizing cigarette smoke, both through activating and detoxifying reactions.  Because 
the level of genotoxic damage in individuals is the result of complex gene-environment and 
gene-gene interactions, genetic variants within multiple genes may interact and cause 
phenotypes that are less able to detoxify exogenous compounds or create toxic intermediate 
metabolites (77). Specifically, individuals with polymorphisms that increase the activity in 
activating reactions and decrease the activity of inactivating reactions are more susceptible 
to the effects of genotoxic compounds (77).  Therefore, a mutation in any one of these genes 
may have a large impact on the efficiency of biotransformation of toxic compounds and the 
interaction of multiple mutations may increase the susceptibility even further. 
 In summary, clubfoot is a common congenital anomaly that has been recognized for 
hundreds of years.  Despite this attention, very little is known about the etiology.  Recent 
studies have implicated an interaction between maternal smoking and genetic variation as a 
possible cause of clubfoot. Maternal smoking during pregnancy is an important and 
prominent risk factor to study.  In the United States in 2007, the overall rate of cigarette 
smoking during pregnancy was 13.2% and the rate for NHW women (18.1%) was more than 
six times the rate for Hispanic women (2.8%) (105).  This study will analyze the variation 
within specific smoking metabolism genes involved in both phases I and II of cigarette 
smoke metabolism (Figure 8) to determine if this variation, in conjunction with maternal 
smoking, could have an etiologic role in the development of clubfoot in NHW and Hispanic 
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populations.  Findings from this study may offer insight into the etiology, mechanism and 
risk of clubfoot in the nonHispanic white and Hispanic populations. 
 
  Figure 8. Xenobiotic metabolism pathway highlighting the 
role of genes in this study
 
Exogenous xenobiotic compound
Reactive metabolite
Excretion
CYP450s & EH
NAT2 & GSTs
Phase I
Oxidation/Reduction
Phase II
Conjugation
35 
 
MATERIALS AND METHODS 
 
IRB Approval 
This study was reviewed and approved by the Committee for the Protection of 
Human Subjects at the University of Texas Health Science Center (HSC-MS-09-0328) and 
all collaborating centers (see below). 
 
Clubfoot Study Samples and Sample Preparation 
Families in the study data set were identified through a proband at six orthopedic 
centers: Shriners Hospital for Children of Houston and Los Angeles Texas Scottish Rite 
Hospital for Children of Dallas, University of Iowa and University of British Columbia. The 
diagnosis of clubfoot was based on the presence of adducted forefoot, varus hindfoot, and 
ankle equinus deformities and determined by either examination and/or by review of 
medical records.  Only patients with isolated clubfoot were included in the study.  All 
patients with syndromic clubfoot or with multiple malformations were excluded.  
Family history and exposure information were obtained by interview with the 
proband’s mother and/or by chart review.  Ethnicity for each family was recorded based on 
self-reporting.  Only nonHispanic white (NHW) and Hispanic families were included in this 
study.  Two-generation pedigrees were constructed for all families.  Pedigrees were 
extended to include all affected individuals if a positive family history was reported. 
Probands were recorded as having a positive or negative family history, which was used in 
the analysis.  Blood or saliva samples were collected on all available family members.  DNA 
was extracted from the 
blood or saliva using either 
the Roche DNA Isolation 
Kit for Mammalian Blood 
(Roche, Basel, Switzerland) 
or the Oragene Purifier for 
saliva (DNA Genotek, 
INC., Kanata, Ontario, Canada) following the manufacturer’s protocol.   
Total NHW Hispanic 
Multiplex 242 149 92 853
Simplex 377 149 226 923
Total 619 298 318 1776
Family type
Families Total 
Individuals
Table 9. Composition of clubfoot dataset by ethnicity and family 
history
Table . Composition of clubfoot dataset by ethnicity and 
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The study dataset consisted of 1,776 individuals from 619 families (Table 10).  
Families were considered to be multiplex or simplex based on the presence or absence of a 
family history of clubfoot, respectively.  The sample consisted of 242 multiplex families 
(149 NHW and 92 Hispanic) and 377 simplex families (149 NHW and 226 Hispanic). 
 
Gene and SNP Identification and Genotyping 
Candidate genes were selected following a thorough literature search of relevant 
publications.  Hundreds of enzymes are known to play a role in xenobiotic metabolism, 
however only a subset of these enzymes are well-characterized and an even smaller subset 
have been shown to be specifically involved in the metabolism of tobacco smoke.  Only 
genes known to metabolize compounds in cigarette smoke and that interact in multiple steps 
of a common general pathway were included in this study. 
SNPs in the CYP1A1, CYP1A2, CYP1B1, CYP2A6, EPHX1 genes were identified 
using NCBI and Ensembl websites.  SNPs in the NAT2 gene were identified previously (47).  
SNPs were selected based on a standard set of criteria including: heterozygosity >0.3, inter- 
and intragenic positions, coverage of the gene and tagging ability.  SNPs with a higher 
heterozygosity that caused a missense mutation and/or tagged for multiple SNPs were 
preferred.  Many SNPs in the target genes had low heterozygosity.  Information about the 
SNPs identified for this study is presented in Table 11.  Once identified, SNPs were 
genotyped using TaqMan Genotyping Assays (Applied Biosystems, Foster City, CA) and 
detected on a 7900 HT Sequence Detection System (Applied Biosystems).  Results that 
could not be interpreted for any given sample and/or SNP were re-genotyped. All genotype 
data was entered into a Progeny database and checked for incompatibility with Pedcheck.  
Pedigrees with conflicting genotyping results that could not be resolved were eliminated 
from subsequent analyses. 
GSTM1 and GSTT1 
were genotyped to identify 
individuals with wild type 
or null alleles following the 
protocol of Arand et al. 
(1996).  The GSTM1 and 
Figure 9.  Optimized Takara Ex Taq Polymerase PCR protocol
PCR Step
Temp. 
(°C)
Duration
Number of 
repetitions
Primary denaturation 95 2 minutes 1
Denaturation 94 1 minute
Annealing 64 1 minute
Extension 72 1 minute
Final elongation 72 5 minutes 1
30
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GSTT1 alleles were amplified simultaneously via Takara Ex Taq Polymerase PCR (Takara 
Bio USA).  The PCR reaction protocol was modified by an addition of 0.5 µL of MgCl per 
reaction and by using an optimized annealing temperature of 64˚C.  The modified Takara Ex 
Taq Polymerase 
PCR protocol is 
shown in Figure 9.  
The Arand method 
combines primers 
for GSTM1, GSTT1 
and ALB as an 
internal positive 
control into one 
assay (106).  The 
ALB product is 350 
bp in length while the GSTM1 and GSTT1 products are 215 bp and 480 bp long, respectively 
(106).  Amplified samples were run on a 2% agarose gel and scored according to the 
presence of the wild type or null allele for both GSTM1 and GSTT1 (Figure 10).  Individuals 
with an absence of GSTM1 or GSTT1 were scored as having null alleles (106).  Individuals 
showing the presence of GSTM1 or GSTT1 were identified as having at least one allele.  
Discrimination of individuals being heterozygous for GSTM1 and GSTT1 could not be 
achieved using this assay.  
 
Statistical Analysis 
Allele frequencies and Hardy-Weinberg equilibrium (HWE) were calculated using 
SAS (v9.1).  SNPs found to be out of HWE (P<0.001) were identified and excluded from 
the subsequent analyses.  Chi-squared (X
2
) analysis was performed to identify any 
differences in allele frequencies between the NHW and Hispanic populations.  Pair-wise 
linkage disequilibrium (LD) values (D’ and r
2
) were calculated using GOLD (107). 
Linkage and/or association were tested using multiple analytic methods to extract the 
greatest amount of information from the data.  Both parametric and non-parametric linkage 
analyses were performed using Merlin (108). Pedigree Disequilibrium Test (PDT) was 
Figure 10. PCR-PAGE results for GSTT1 and GSTM1 null allele assay
 
Controls
GSTT1 - + + -
Alb - + + +
GSTM1 - + - +
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performed in order to include data pertaining to individuals in larger pedigrees (109).  PDT 
uses all of the informative data in a pedigree, is valid when population substructure is 
present and remains powerful if there is misclassification of unaffected individuals (109).  
The genotype-pedigree disequilibrium test (geno-PDT) was also used to include the 
information from families with multiple affected individuals (110).  Geno-PDT tests for 
patterns of association at the genotypic level (110).  Association in the Presence of Linkage 
(APL) tests for association and 2-SNP haplotypes within a gene and can use all genotype 
information even when a parental genotype is missing (111).  Generalized estimating 
equations (GEE) was used to detect gene-gene and gene-environment interactions (112).   
Log-linear regression models were used to evaluate the independent effects of 
maternal and child genotypes.  Information on maternal, paternal and child genotypes were 
coded and analyzed using LEM software (113).  To prevent any violations of the assumption 
of independence between each unit of analysis (each triad), only one triad was selected per 
family (where, child = proband).  For each SNP, log-likelihoods were computed for the full 
models (including both maternal and child genotypes) and compared to the log-likelihoods 
computed for partial models (including either the maternal genotype or the child genotype 
only).  The resulting two log-likelihood ratios (LLR) were considered to be statistically 
significant at p<0.05. 
Chi-square analysis was used to evaluate the relationship between smoking and 
clubfoot in the presence of null GSTM1 or GSTT1 alleles.  The relationship between GSTM1 
and GSTT1 null allele status and smoking/exposure status were analyzed for probands and 
mothers of probands.  Additionally, maternal and paternal null allele status was analyzed to 
determine if more mothers than fathers of probands possess the null allele genotype. 
 
Protein function analyses and identification of transcription factor binding sites 
In silico analyses of significant exonic missense mutations were performed using 
SNPs3D and Polyphen to estimate the effect of the ancestral and alternate alleles on protein 
function (114, 115).  The ancestral and alternate allele sequences were obtained from the 
NCBI Entrez SNP Database (www.ncbi.nlm.nih.gov).   
In silico analyses of the overtransmitted SNP sequence present in a potential 
regulatory region were performed using Alibaba2, Patch and Transcription Element Search 
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Software (TESS) (116-118).  The ancestral and alternate allele sequences were obtained 
from the NCBI Entrez SNP Database (www.ncbi.nlm.nih.gov).   
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RESULTS  
 
Twenty-two SNPs and two null alleles in eight genes, CYP1A1, CYP1A2, CYP1B1, 
CYP2A6, EPHX1, NAT2, GSTM1 and GSTT1, were genotyped in our NHW and Hispanic 
families (Table 11).   All SNPs had call rates of >95%.  All SNPs were in HWE in the NHW 
group (Supp. Table 1A).  In the Hispanic subset, rs1048943 (p=0.02), rs2470893 (p=0.0004) 
and rs4105144 (p=0.01) were not in HWE and excluded from further analysis (Supp. Table 
1B).    
Allele frequencies for 16 of the 22 SNPs differed between the NHW and Hispanic 
groups (Table 11); therefore the data was stratified by ethnicity.  In addition, the data was 
further stratified by the presence or absence of family history (FH) of clubfoot.  The LD 
plots for each of the 22 SNPs are similar between ethnicities and between unaffected and 
affected individuals (Supp. Table 2).   
In the NHW aggregate group, SNPs in four genes (CYP1A1 (p=0.003), CYP1A2 
(p=0.03), CYP1B1 (p=0.05) and EPHX1 (p=0.05)) showed altered transmission (Table 12).   
rs1048943 in CYP1A1 (p=0.009) also showed altered transmission in the  NHW multiplex 
families as did the rs2234922 in EPHX1 (p=0.05).  Two SNPs in CYP1B1 demonstrated 
altered transmission in the NHW simplex families as did one SNP in NAT2.  None of the 
two-SNP haplotypes showed altered transmission in this group (Supp. Table 3A). 
For the Hispanic group, no SNPs showed altered transmission in the aggregate group 
(Table 12).   rs7250713 (p=0.01) in CYP2A6 and rs360063 (p=0.04) in EPHX1 showed 
altered transmission in the multiplex family subset, whereas rs1456432 (p=0.03) in CYP1A1 
and rs360063 (PDT: p=0.03; APL: p=0.01) in EPHX1 were altered in the simplex families.  
None of the two-SNP haplotypes showed altered transmission (Supp. Table 3B). 
Strong evidence for a gene interaction was seen only in the NHW group between rs105740 
in EPHX1 and rs1799929 in NAT2 (p=0.007) (Table 13).  Suggestive evidence for 
interactions was found for SNPs in CYP2A6 and SNPs in CYP1B1, EPHX1 and NAT2.  
There was minimal evidence for gene interactions in the Hispanic group. 
Regression modeling was used to evaluate the independent effects of maternal and child 
genotypes.  Only two SNPs showed evidence of a genotypic effect (Table 14).  For 
rs11854147, a significant maternal genotypic effect (p= 0.03) was found with a relative risk  
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Gene SNP Bp # Alleles
a Location Type
b cDNA 
Change
Protein 
Change
 MAF HCF
c
rs2470893 72806502 G/A Upstream - - - 0.30 0.13
rs1048943 72800038 A/G Exon 7 M 1384A>G Ile462Val 0.04 0.35
rs1456432 72790104 G/A Downstream - - - 0.16 0.44
rs2472299 72820453 G/A Upstream - - - 0.28 0.27
rs2470890 72834479 C/T Exon 7 S 1548T>C Asn516Asn 0.37 0.68
rs11854147 72839824 C/T Downstream - - - 0.33 0.61
rs4646429 38160439 A/G Upstream - - - 0.32 0.31
rs10012 38155894 G/C Exon 2 M 142C>G Arg48Gly 0.32 0.33
rs1056836 38151707 G/C Exon 3 M 1294C>G Leu432Val 0.42 0.25
rs163084 38144420 T/C Downstream - - - 0.20 0.14
rs4105144 46050464 C/T Upstream - - - 0.32 0.25
rs7250713 46047035 C/G Intron 2 - - - 0.40 0.34
rs7246742 46037235 G/T Downstream - - - 0.13 0.18
rs2854450 224079200 C/T Upstream - - - 0.20 0.18
rs1051740 224086256 T/C Exon 3 M 337T>C Tyr113His 0.30 0.41
rs2234922 224093029 A/G Exon 4 M 416A>G His139Arg 0.17 0.08
rs360063 224102932 G/A Downstream - - - 0.44 0.48
rs1041983 18302075 C/T Exon 2 S 282C>T Tyr94Tyr 0.33 0.31
rs1801280 18302134 T/C Exon 2 M 341T>C Ile114Thr 0.44 0.32
rs1799929 18302274 C/T Exon 2 S 481C>T Leu161Leu 0.42 0.32
rs1799930 18302383 G/A Exon 2 M 590G>A Arg197Gln 0.30 0.18
rs1799931 18302650 G/A Exon 2 M 857G>A Gly286Glu 0.04 0.13
WT/null - null - null 0.47 0.56
WT/null - null - null 0.20 0.13
Table 10. Smoking metabolism genes: SNP location, alleles and ethnic frequencies
GSTM1
CYP1A1 
15q22-24 
5.99kb
CYP1A2 
15q22-qter 
7.76kb
CYP1B1 
2p22-p21 
8.55kb
CYP2A6 
19q13.2   
6.90kb
EPHX1 
1q42.1   
20.29kb
NAT2  
8p23.1-p21.3 
9.97kb
c
 Values in bold = HCF significantly different from MAF [P <0.01]
GSTT1
MAF = minor allele frequency in nonHispanic White sample; HCF = Hispanic corresponding frequency to NHW minor allele
a
 Ancestral allele/Alternate allele
b 
Type of Mutation: M = Missense; S = Synonymous
WT = wildtype
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A. NHW
PDT
GENO-
PDT
APL PDT
GENO-
PDT
APL PDT
GENO-
PDT
CYP1A1 rs1048943 0.003 0.003 0.12 0.009 0.009 0.71 0.17 0.17
CYP1A2 rs2472299 0.85 0.29 0.03 0.61 0.22 0.27 0.21 0.43
CYP1B1 rs1056836 0.53 0.76 0.14 0.92 0.93 0.81 0.13 0.14
CYP1B1 rs163084 0.10 0.14 0.05 0.40 0.59 0.40 0.05 0.04
EPHX1 rs2234922 0.05 0.09 0.13 0.05 0.06 0.06 0.73 0.68
NAT2 rs1799931 0.12 0.07 0.55 0.59 0.70 0.41 0.01 0.01
* results for (p≤0.05)
B. Hispanic
PDT
GENO-
PDT
APL PDT
GENO-
PDT
APL PDT
GENO-
PDT
CYP1A1 rs1456432 0.44 0.68 0.52 0.39 0.70 0.37 0.03 0.12
CYP2A6 rs7250713 0.37 0.17 0.74 0.88 0.39 0.01 0.25 0.20
EPHX1 rs360063 0.62 0.13 0.28 0.42 0.08 0.04 0.03 0.15
* results for (p≤0.05)
Table 11. Results of single SNP association analysis by family history 
Gene dbSNP
All Multiplex Simplex
All Multiplex Simplex
Gene dbSNP
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of 1.24 (95% CI: 1.04-1.44).   A significant fetal 
genotypic effect (p= 0.01), with a relative risk of 
1.33 (95% CI: 1.13-1.54), was found for rs2470890. 
The single SNP association analysis detected 
altered transmission of four nonsynonymous exonic 
SNPs.  To assess whether these SNPs are expected to 
affect the overall protein stability and function, we 
utilized SNPs3D (SNPs3D.org) and Polyphen 
(http://genetics.bwh.harvard.edu/pph/) prediction 
models.  rs1799930 is predicted to either affect the 
NAT2 protein stability by altering bond and 
interaction strength (SNPs3D.org) or to be benign.  
rs1048943, in CYP1A1, is predicted to be a harmless 
alteration, but is surrounded by SNPs that may affect 
protein structure stability.  rs1056836, in CYP1B1 is 
predicted to be deleterious to the protein stability or 
to be benign while the rs2234922 variant in EPHX1 
is benign.   
We also found evidence of association for SNPs 
that are located 5’ upstream of CYP1A2 and CYP2A6 
in potential regulatory regions.  Three transcription 
factor binding site (TFBS) prediction algorithms 
were used to assess whether these SNPs could play a 
role in gene regulation (Table 15).  One SNP, 
rs2472299 in CYP1A2, showed evidence for 
association in the NHW group and marginal 
evidence of gene-gene interactions in the Hispanics.  All three algorithms predicted that the 
alternate rs2472299 allele eliminates a glucocorticoid receptor (GR) TFBS.  Evidence for 
gene-gene interaction was found for rs4105144 in CYP2A6 in the NHW group and the 
alternate allele was predicted to create a TFBS, although the type of TFBS differed (Table 
15).   
Gene 1 
SNP 1
Gene 2 
SNP 2
P -
Value
EPHX1 
rs1051740
NAT2 
rs1799929
0.007
CYP1B1 
rs1056836
CYP2A6 
rs4105144
0.02
EPHX1 
rs1051740
NAT2 
rs1801280
0.03
EPHX1 
rs360063
CYP2A6 
rs4105144
0.04
NAT2 
rs1799930
CYP2A6 
rs4105144
0.04
EPHX1 
rs2234922
CYP2A6 
rs7246742
0.05
EPHX1 
rs1051740
CYP2A6 
rs7250713
0.05
Gene 1 
SNP 1
Gene 2 
SNP 2
P -
Value
CYP1B1 
rs1056836
NAT2 
rs1799929
0.04
CYP1A1 
rs1456432
CYP1A2 
rs2472299
0.04
CYP1B1 
rs1056836
NAT2 
rs1801280
0.04
CYP1B1 
rs163084
NAT2 
rs1799929
0.05
CYP1B1 
rs1056836
CYP1A2 
rs2472299
0.05
Table 12. Gene-gene interactions 
A. NHW
B. Hispanic
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Table 13. Results of log-linear regression modeling of genotypes for mothers and children
Child Mother Child Mother
rs2470890 1.33 (1.13-1.54) 1.23 (1.02-1.45) 0.01 0.06
rs11854147 1.19 (0.99-1.39) 1.24 (1.04-1.44) 0.09 0.03
Gene
CYP1A2
a 
Relative Risk
b
 Log-likehood ratio test
SNP RR
a 
(95% CI) LRT
b 
p -value
Ancestral Alternate Ancestral Alternate Ancestral Alternate
CYP1A2 / 
rs2472299
8.7 kb 
upstream
GR None GR, AR None GR, AR None
CYP2A6 / 
rs4105144
2.3 kb 
upstream
None PU.1 None None Bcd, Ft2.2 LEF
GR = Glucocorticoid receptor; AR = Androgen receptor; Bcd = Bicoid; LEF = Lymphoid Enhancer Factors
Table 14. Predicted transcription factor binding sites for 5' associated SNPs
Gene/SNP
Alibaba2 Patch TESS
Alleles Alleles AllelesLocation
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Because GSTM1 and GSTT1 null alleles play a significant role in the variation of 
xenobiotic metabolism between individuals, we assessed the relationship between null 
genotypes and the risk for clubfoot.  Maternal smoking status was known for 276 NHW 
probands (yes=65; no=211) and 326 Hispanic probands (yes=15; no=311). Of the 
individuals genotyped for the GSTM1 and GSTT1 alleles, 195 NHW probands had smoking 
data available (yes=48; no=147) and 251 Hispanic probands had smoking data available 
(yes=9; no=242).  Smoking during pregnancy was reported by 13% of the mothers.  Forty-
seven percent of individuals genotyped were homozygous for the GSTM1 null allele and 
18% for GSTT1 null allele, which is consistent with previous reports (88).  The data were 
analyzed in aggregate and by ethnicity.  In the NHW group, smoking was evaluated as a 
covariate for the individual alleles.  This analysis could not be performed in the Hispanic 
subset because of limited information.  For the aggregate and NHW groups, there was no 
evidence for an association between in utero exposure to maternal smoking and GSTM1 or 
GSTT1 genotype (Table 16).  There was also no relationship between maternal smoking and 
the mother’s genotype and the risk for clubfoot for either gene.  In addition, there was no 
difference in the percentage of null mothers versus null fathers for either gene for either 
ethnic group.   
  
X
2 p -value X
2 p -value
All Proband + Smoking exposure 0.42 0.52 0.05 0.83
All Maternal + Smoking exposure 0.04 0.84 0.07 0.80
All Maternal + Paternal 2.12 0.15 1.03 0.31
NHW Maternal + Paternal 2.15 0.14 0.30 0.58
Hisp Maternal + Paternal 0.50 0.48 0.60 0.44
Genotype
GSTM1 GSTT1
Table 15.  Results for  GSTM1  and GSTT1  analysis
Dataset
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DISCUSSION 
 
Numerous studies throughout history have sought to explain the etiology and identify the 
risk factors for isolated clubfoot.  Both genes and environmental factors are speculated to 
contribute to clubfoot, although the exact roles of each still need to be defined.  Candidate 
gene analysis is beginning to uncover etiologic gene pathways for clubfoot. For example, 
apoptotic genes, such as Casp8/10 and Casp3, as well as HOX genes important for 
embryologic limb development have recently been reported to be associated with clubfoot 
(48, 49).  While other genes contributing to clubfoot are yet to be discovered, maternal 
smoking remains the only common environmental risk factor that has consistently been 
shown to increase the risk of clubfoot (22, 37, 38).  In addition, the risk of clubfoot is 
significantly increased for women who smoke during pregnancy and have a positive family 
history (37).  These findings suggest that genetic variation in smoking metabolism genes 
may increase susceptibility to clubfoot.  Based on this reasoning, we interrogated eight 
candidate genes, chosen based on their involvement in cigarette smoke metabolism (63, 80, 
98).  SNPs in six of these genes were chosen based on their frequency, functionality and 
location within the gene.  In addition, two null alleles in GSTM1 and GSTT1 were assessed 
because of their known role in phase II of tobacco metabolism (57, 88). 
Considering the strength of the association between clubfoot and smoking from previous 
population-based studies, there was surprisingly minimal evidence for a role of variation in 
these eight genes.  The strongest evidence for association was for CYP1A1 (rs1048943; 
p=0.003) in the NHW dataset in the single SNP analysis. The variant is a missense mutation 
(1384A>G) in exon 7 that changes an isoleucine to a valine at amino acid position 462 
(www.ncbi.nlm.nih.gov/) and confers higher phase I enzymatic activity, which may increase 
exposure to harmful, adduct forming, metabolic intermediates (75, 76).  Another CYP1A1-
related SNP, rs1456432, gave minimal evidence of altered transmission in the Hispanic 
group.  This SNP is located 9.1 kb downstream of CYP1A1 and therefore, may play a role in 
regulation of the gene by affecting an enhancer region or stabilization of the mRNA (119).  
One other significant finding was the interaction between rs1051740 in EPHX1 and 
rs1799929 in NAT2 (p=0.007).  EPHX1’s major role in phase I of tobacco smoke 
metabolism is hydrolysis of PAH (80, 86).  As previously discussed, the rs1051740 variant 
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has decreased activity and has been associated with decreased DNA adduct formation (59, 
77).  NAT2 plays an important role in phase II reactions of tobacco smoke metabolism (98).  
The rs1799929 variant allele in NAT2 codes for a synonymous amino acid change in exon 2, 
which could decrease the rate of NAT2 translation (120).  Additionally, NAT2 is known to 
have variants with decreased activity, though the in vivo effect of the rs1799929 on enzyme 
activity is not known and may or may not confer a “slow acetylator” phenotype (100).   
While SNP associations do not imply causation, they can indicate that variation in, near 
and/or in linkage disequilibrium with these SNPs may be causative.  There are many ways 
SNPs can cause or can be related to SNPs that cause the observed associations.  One 
interpretation of our results is that perturbation of phase I reactions of xenobiotic 
metabolism that increase enzyme activity and adduct formation may play a role in the 
development of clubfoot.  Compounds from cigarette smoke form DNA and protein adducts, 
which can cause mutagenesis and teratogenesis (52, 56, 59).  Additionally, simultaneous 
increase in phase I activity with a perturbation in phase II activity may also play a role.  
Because phase I xenobiotic metabolism genes create harmful metabolic intermediates in the 
normal biotransformation pathway, it may be that an increase in phase I enzyme activity and 
a decrease in phase II degradation of these intermediates increases the concentration of 
harmful compounds to damaging levels that can interfere with fetal development.  Some of 
the metabolic intermediates known to be produced by phase I xenobiotic metabolism are 
active oxygen species and DNA or protein binding adducts (50).  While it has been 
suggested that harmful oxygen species and adducts can interfere with normal fetal 
development, the role of these compounds in the pathogenesis of clubfoot is unknown (57, 
121, 122).  Our results suggest that an increase in harmful metabolic intermediates could 
contribute to abnormal foot development or rotation of the foot. 
Our results also identified other marginal associations and gene interactions that could 
potentially be important.  Many of these SNP variants are known or predicted to alter the 
function of the gene and may impact the efficiency of the xenobiotic metabolism pathway 
by perturbing the activity of phase I and/or phase II.  While these associations and 
interactions are marginal, they suggest that many gene variants and/or interactions could be 
important and may perturb different parts of the xenobiotic metabolism pathway, and 
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thereby contribute to clubfoot causality.    Additional studies are needed to further explore 
these potential interactions.   
One such association involves SNPs in CYP1A2 (rs2472299, rs1056836) and rs163084 
in CYP1B1, which had marginal evidence for association in the NHW dataset only. The 
rs2472299 polymorphism is 8.7 kb upstream of the CYP1A2 gene and is predicted to abolish 
a glucocorticoid receptor or androgen receptor transcription factor-binding site.  These 
results suggest that the variant may alter transcription of CYP1A2 and decrease the 
efficiency of the metabolic pathway (116-118).  Previous studies that have considered the 
effects of SNPs in CYP1B1 and have suggested that rs1056836 alone may alter CYP1B1 
function by decreasing metabolism of benzo(a)pyrene (BaP) metabolites (BaP-7,8-
dihydrodiols) and increasing metabolism of the parent compound (BaP), which would 
increase DNA adduct formation (59, 77).  CYP1A2 and CYP1B1 both play a role in phase I 
xenobiotic metabolism, and one possible effect of increased phase I enzymatic activity is a 
build up of intermediate metabolites.  Therefore, harmful metabolic intermediates may have 
a greater impact due to a more substantial “exposure” (59).  For example, BaP, a prototypic 
PAH, is first metabolized to an epoxide by CYP1A1 and CYP1B1 (60, 61) (Figure 17).  The 
end-product of phase I metabolism of BaP is a highly reactive diol-epoxide, which can form 
DNA adducts (Nock, et al., 2007). 
Additionally, an intronic SNP in CYP2A6, rs7250713, had altered transmission in 
Hispanic multiplex families.  Intronic SNPs have been associated with a dysregulation of 
splice-variant expression and have been shown to produce truncated/non-functional protein, 
which could alter pathways or gene activity and play a role in disease pathogenesis (123, 
124).  However, because SNPs are markers for susceptibility and rs7250713 is not near an 
exonic-intronic junction, our results most likely indicate that variation in CYP2A6 or nearby 
genes may play a role in the etiology of clubfoot. 
rs1799931 in NAT2 also had marginal evidence of association in the single SNP analyses 
only in NHW simplex cases.  This SNP encodes a missense mutation that changes a glycine 
to a glutamine in the mature protein (www.ncbi.nlm.nih.gov/snp/) and is predicted to affect 
protein stability (SNPs3D.org).  The activity of this SNP in vivo is unknown and the activity 
in vitro is controversial, showing decreased activity in Chinese hamster ovary (CHO) cells 
and unstable protein formation with maximum enzymatic velocity not significantly different 
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from wildtype in E. coli (100, 125, 126).  Our result supports the finding by Hecht, et al., 
2007, which found suggestive evidence for an association with rs1799931 in both NHW and 
Hispanic simplex families.  However, in that study a more significant association was found 
for the Hispanic simplex families suggesting that this variant may be a greater risk factor in 
the Hispanic population.  The current results suggest that variation in NAT2 may also be an 
important risk factor for the NHW population.  A larger Hispanic dataset is needed to 
determine whether this is indeed a risk factor in that group. 
In addition to the significant interaction between EPHX1 and NAT2, a marginal 
interaction was found between rs1051740 in EPHX1 and rs1801280 in NAT2, which causes 
a “slow acetylator” phenotype (100, 102, 103).  Interestingly, we observed a marginal 
interaction between rs1056836 in CYP1B1 and the same NAT2 SNPs seen in the interactions 
with EPHX1, rs1799929 and rs1801280.  EPHX1 and CYP1B1 interact through sequential 
reactions in phase I metabolism of PAH and NAT2 is a well-characterized phase II enzyme 
with variants that have been shown to cause an increase in harmful adduct levels (59, 100, 
101).  These results also support the findings by Hecht, et al., 2007 and provide additional 
evidence that NAT2 may play a role in clubfoot.  In addition, these results support the 
conclusions that perturbation of phase I and phase II enzymatic activity may lead to an 
increased risk of clubfoot.  Other marginal but potentially interesting interactions were 
found for different phase I xenobiotic metabolism genes. These interactions involved 
CYP1B1 with CYP1A1, CYP1A2 and CYP2A6, and multiple SNPs in EPHX1 and CYP2A6.  
These results are intriguing when the functional effect of the SNPs and the possible effect on 
the metabolic pathway are considered (Table 17).  In general, we found interactions between 
polymorphisms with variants that are known to alter the activity of the phase I enzyme or 
could affect regulation of the gene.  Although the these findings need to be further explored, 
collectively these results support the hypothesis that disruption of normal activity in both 
phase I and II of xenobotic metabolism can increase the concentration of harmful 
intermediates and may play a role in clubfoot.   
GSTM1 and GSTT1 also play a role in phase II of tobacco smoke metabolism and the 
null alleles of both genes cause absence of enzymatic activity (57).  Loss of activity causes 
an increased susceptibility to DNA adducts and could increase harmful metabolic 
intermediates (88, 92-94, 97).  Interestingly, our results provide no support for a relationship 
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between a homozygous null allele at either locus and an increased risk of clubfoot, even in 
the presence of smoking.  However, these results must be carefully interpreted because 
heterozygotes cannot be discriminated from homozygous wildtype individuals.  The GST 
null alleles likely act as a recessive system in which both null alleles must be present (88, 
97).  Based on this assumption, the phenotype would be anticipated only in the homozygous 
null individuals who have little or no residual enzymatic activity.  Therefore, our results 
suggest that GSTM1 and GSTT1 null alleles, whether they are present in the fetus or the 
mother, are not associated with an increased risk of clubfoot when a mother smokes during 
pregnancy. 
Because both the maternal and fetal smoking metabolism genes may affect the risk for 
clubfoot, we evaluated whether each SNP possessed an independent maternal genetic effect 
(maternal genotype confers a risk) or an independent inherited genetic effect (fetal genotype 
confers a risk).  The maternal effects calculation allows us to compare the role of the 
maternal and/or the fetal genotype on the risk for clubfoot and to obtain relative risks for 
each genotype (113).  For CYP1A2, we found a significant deleterious effect for rs11854147 
(p=0.03; RR=1.24; 95% CI: 1.04-1.44) in the mother and for rs2470890 (p=0.01; RR=1.33; 
95% CI: 1.13-1.54) when in the fetus.  This suggests that either rs11854147 or rs2470890 
can increase the risk of clubfoot but the mechanisms differ based on either whether it is a 
maternal or fetal genotype.  Differences in the gene expression, induction and enzyme 
activity between maternal and fetal tobacco metabolism genes have been reported and these 
results would support evidence that variants in tobacco metabolism genes have different 
consequences when they are of maternal and/or fetal origin (57, 62, 71).  Differentiating risk 
based on maternal and child genotypes as well as interactions between the two genotypes 
will be important for elucidating the role of smoking in the etiology of clubfoot.  Future 
studies need to evaluate maternal and fetal combinations to determine genotypic effects and 
to whether the information can be used to predict pregnancy outcomes. 
 Interestingly, although an association between xenobiotic metabolism genes and 
clubfoot was found, we were unable to confirm the association between maternal smoking 
and clubfoot reported in other studies (22, 37-39).  This may partly be explained by the fact 
that only 13% of women reported smoking during pregnancy in this dataset.  In 
epidemiological studies that have found an association between maternal smoking and 
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clubfoot, an average of 30% of mothers reported smoking during their pregnancy (37-39).  
Additionally, our dataset consists of a majority of Hispanic probands (54%) while 
epidemiological studies looked predominantly at NHW probands (average of 81% NHW).  
Therefore, there are clear differences between our dataset and the epidemiological datasets, 
which may explain why we did not observe more significant results.  Because smoking does 
not appear to be as great a risk factor in our population, we would not expect to see strong 
associations between xenobiotic metabolism genes and clubfoot.  Evaluation of the role of 
xenobiotic metabolism genes in a dataset for which smoking is found to increase the risk of 
clubfoot may reveal stronger associations between these genes and clubfoot and should be 
explored in future studies. 
 Alternatively, our results could suggest that xenobiotic metabolism genes play a role 
in clubfoot that is independent of smoking because these genes are known to have other 
roles in metabolizing compounds not found in cigarette smoke, such as prostaglandins and 
other endogenous hormones (127).  For example, CYP1A1, 1A2 and 1B1 play a role in the 
metabolism of estradiols, which are important in maintaining a pregnancy and have been 
shown to increase blood flow in coronary arteries (127, 128).  Estradiols may also increase 
blood flow in other organs, such as the placenta, and therefore, increased metabolism of 
these hormones may contribute to a decreased availability of oxygen and nutrients to a 
developing fetus.  Additionally, CYP2A6 metabolizes approximately 1% of over-the-counter 
and prescription drugs as well as many environmental toxins (127).  Therefore, xenobiotic 
metabolism genes may impact the risk of clubfoot by altering the metabolism of multiple 
exogenous and endogenous compounds besides tobacco smoke.   
 If tobacco smoke exposure is not affecting the fetus through the xenobiotic 
metabolism pathway, it may play a role in the etiology of clubfoot by other mechanisms.  
For example, early amniocentesis also increases the risk of clubfoot suggesting that a 
common teratogenic mechanism may be common to both exposures.  The simplest 
explanation would be vascular insufficiency and hypoxia that would deprive the fetus of 
blood flow and necessary nutrients.  Maternal smoking and nicotine exposure in mice 
specifically reduces blood flow and increases vascular resistance in the uterus (129-132). 
Moreover, mice exposed to PAHs have been shown to have abnormal vasculature in the 
placenta that significantly reduces arterial surface area and volume of the fetal arterial 
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vasculature (56).  Reduction in vascular efficiency and an increased susceptibility to hypoxia 
could cause abnormal limb development and has been shown to cause transverse limb 
defects in prolonged (30-60 minutes) cases of anoxia (139).  Therefore, variable degrees of 
hypoxia may increase the risk of other limb abnormalities, the most mild of which would be 
clubfoot.  Interestingly, aborted fetuses with homozygous alpha-thalassemia, a genetic 
condition known to cause severe fetal anemia and hypoxia, experience transverse limb 
defects with the feet more severely affected than the hands (133).  These effects may be 
specific to the developing foot depending on the timing of the hypoxic event, the intricate 
and complicated nature of the developing foot and/or a strategy for a fetus to conserve 
nutrients and oxygen to more essential body parts and organs.   
The targeted effect of both maternal smoking and early amniocentesis is possible 
reduction in fetal movements that are necessary for joint, vascular and soft tissue 
development (134, 135).  Decreased fetal movement leads to or contributes to joint and limb 
anomalies in mouse models and humans (134, 136).  Therefore, the association between 
maternal smoking and clubfoot might be explained by the direct effect of tobacco on in 
utero fetal lower limb movement.  Although there is no clear relationship between maternal 
tobacco smoking and early amniocentesis, they both confer an increased risk for clubfoot.  It 
is possible that they share a common mechanism that is responsible for an increased risk of 
clubfoot, although the exact mechanism(s) requires additional study.   
The results of this study are important but must be carefully interpreted until larger 
validation studies can be undertaken.  As previously discussed, smoking data was reported 
by 13% (n=80) of our mothers and is consistent with that reported by pregnant women in the 
general population (105).  However, this translates into a relatively small number of 
smoking mothers upon which to base our analyses and limits the ability to detect an effect 
that is not large.  This is particularly striking for the GST null allele analyses (137, 138).   
Additionally, this study focused on only eight of the most important tobacco smoke 
metabolism enzymes.  There are likely hundreds of genes involved in the overall 
biotransformation of the compounds found in tobacco smoke, which were not considered in 
this study.  While the genes in this study are the most likely candidates, we cannot rule out 
that other genes play a major role or interact with the genes in this study and contribute to 
the clubfoot phenotype. 
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Previous epidemiologic and molecular research has shown that maternal smoking is 
associated with an increased risk of clubfoot and variation in smoking metabolism genes can 
cause an increase in harmful metabolic intermediates that may lead to a variety of birth 
defects (37, 38, 100, 121, 122).  To better understand this relationship and to identify the 
possible role of smoking metabolism in the etiology of clubfoot, we examined the 
relationship between polymorphic variants in smoking metabolism genes and clubfoot in a 
dataset of well characterized multiplex and simplex clubfoot families for which prenatal 
exposure to cigarette smoke was known.  Interestingly, no association was found between 
maternal smoking and clubfoot.  This may indicate that the genes in this study play a role 
that impacts the developing fetus regardless of cigarette smoke exposure or they play a 
larger role in the development of clubfoot for populations in which smoking is found to be a 
risk factor.  However, our results suggest that there is an association between CYP1A1 and 
an interaction between EPHX1 and NAT2 xenobiotic metabolism genes and an increased 
risk for clubfoot.  Additionally, we observed multiple marginal associations and gene 
interactions in other xenobiotic metabolism genes, suggesting that these genes may also play 
a role in the etiology of clubfoot.  The genes in this study are likely to interact in pathways 
that affect fetal development, possibly by altering blood flow to the developing fetus, 
causing changes in hormonal metabolism, inducing fetal hypokinesia or some other 
mechanism.  Further studies are needed to better delineate the role of xenobiotic metabolism 
genes during pregnancy and the effects of polymorphisms on the developing fetus. 
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Appendix A 
 
 
 
Supplementary Tables 
 
 
 
             Supplementary Table 1. Hardy-Weinberg equilibrium results  
A. NHW
Gene SNP No. PIC Het. X
2 p -
value
CYP1A1 rs1048943 439 0.08 0.08 0.02 0.88
rs1456432 434 0.23 0.29 2.32 0.13
rs2470893 436 0.33 0.43 0.14 0.71
CYP1A2 rs1185414 430 0.34 0.44 0.01 0.92
rs2470890 433 0.36 0.48 0.19 0.66
rs2472299 429 0.32 0.42 0.41 0.52
CYP1B1 rs10012 428 0.34 0.42 0.22 0.64
rs1056836 439 0.37 0.53 2.80 0.09
rs163084 441 0.27 0.34 0.97 0.32
rs4646429 435 0.34 0.43 0.01 0.91
CYP2A6 rs4105144 423 0.34 0.41 1.56 0.21
rs7246742 443 0.20 0.21 0.59 0.44
rs7250713 440 0.37 0.45 2.15 0.14
EPHX1 rs1051740 430 0.33 0.44 1.31 0.25
rs2234922 438 0.25 0.28 0.36 0.55
rs2854450 439 0.27 0.31 0.08 0.77
rs360063 436 0.37 0.48 0.14 0.71
NAT2 rs1041983 433 0.35 0.44 0.01 0.92
rs1799929 429 0.37 0.48 0.02 0.88
rs1799930 427 0.33 0.41 0.34 0.56
rs1799931 429 0.07 0.07 0.37 0.54
rs1801280 432 0.37 0.50 0.13 0.72
GSTM1  - 392 0.37 0.00 392.00 <.0001
GSTT1  - 393 0.27 0.00 393.00 <.0001  
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              Supplementary Table 1. Hardy-Weinberg equilibrium results (cont.) 
Gene Locus No. PIC Het. X
2 p -
value*
CYP1A1 rs1048943 416 0.35 0.40 5.19 0.02
rs1456432 416 0.37 0.50 0.10 0.75
rs2470893 415 0.20 0.19 12.55 0.00
CYP1A2 rs1185414 422 0.36 0.44 2.33 0.13
rs2470890 414 0.34 0.41 1.07 0.30
rs2472299 419 0.32 0.42 0.76 0.38
CYP1B1 rs10012 408 0.34 0.44 0.02 0.88
rs1056836 415 0.30 0.37 0.00 0.96
rs163084 421 0.21 0.25 0.38 0.54
rs4646429 418 0.33 0.43 0.04 0.84
CYP2A6 rs4105144 402 0.31 0.33 6.13 0.01
rs7246742 419 0.26 0.31 0.14 0.71
rs7250713 409 0.35 0.42 1.12 0.29
EPHX1 rs1051740 418 0.37 0.46 0.97 0.32
rs2234922 421 0.13 0.15 0.99 0.32
rs2854450 416 0.25 0.30 0.38 0.54
rs360063 421 0.37 0.51 0.14 0.71
NAT2 rs1041983 412 0.33 0.44 0.35 0.56
rs1799929 406 0.34 0.44 0.10 0.76
rs1799930 405 0.26 0.32 1.50 0.22
rs1799931 409 0.20 0.22 0.38 0.54
rs1801280 409 0.34 0.45 0.55 0.46
GSTM1  - 399 0.37 0.00 399.00 <.0001
GSTT1  - 399 0.20 0.00 399.00 <.0001
*Bolded values are not in HWE and were excluded from our analyses
PIC = Polymorphic information content
B. Hispanic
No. = number of individuals
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Supplementary Table 2. Linkage disequilibrium (D') for SNPs in smoking metabolism genes by chromosome 
a,b
 
rs1051740 rs2234922 rs2854450 rs360063
rs1051740 0.083 0.191 0.594
rs2234922 0.073 0.076 1.000
rs2854450 0.422 0.014 0.349
rs360063 0.539 0.951 0.238
rs163084 rs1056836 rs10012 rs4646429
rs163084 0.942 1.000 1.000
rs1056836 0.949 0.982 0.982
rs10012 1.000 0.987 1.000
rs4646429 1.000 0.987 1.000
rs1041983 rs1801280 rs1799929 rs1799930 rs1799931
rs1041983 0.984 0.983 0.971 1.000
rs1801280 0.979 1.000 0.960 1.000
rs1799929 0.967 0.995 0.957 1.000
rs1799930 0.962 0.987 0.987 1.000
rs1799931 1.000 1.000 1.000 1.000
rs1456432 rs1048943 rs2470893 rs2472299 rs2470890 rs11854147
rs1456432 1.000 1.000 0.634 0.259 0.211
rs1048943 1.000 0.999 0.252 0.640 0.619
rs2470893 1.000 1.000 0.842 0.870 0.889
rs2472299 0.721 0.272 0.861 0.989 0.981
rs2470890 0.285 0.694 0.904 1.000 0.901
rs11854147 0.281 0.508 0.887 0.987 0.922
rs7246742 rs7250713 rs4105144
rs7246742 0.190 1.000
rs7250713 0.117 0.989
rs4105144 0.815 0.987
Chromosome 19 (CYP2A6 )
Chromosome 15 (CYP1A1, CYP1A2 )
Chromosome 1 (EPHX1 )
Chromosome 2 (CYP1B1 )
Chromosome 8 (NAT2 )
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Supplementary Table 2. Linkage disequilibrium (D') for SNPs in smoking metabolism genes by chromosome 
a,b
 (cont.) 
B. Hispanic
rs1051740 rs2234922 rs2854450 rs360063
rs1051740 0.559 0.769 0.120
rs2234922 0.418 0.109 1.000
rs2854450 0.585 0.227 0.311
rs360063 0.123 1.000 0.503
rs163084 rs1056836 rs10012 rs4646429
rs163084 1.000 1.000 1.000
rs1056836 0.948 0.564 0.842
rs10012 0.926 0.694 0.982
rs4646429 1.000 1.000 0.994
rs1041983 rs1801280 rs1799929 rs1799930 rs1799931
rs1041983 0.973 0.973 0.951 0.975
rs1801280 1.000 0.991 1.000 1.000
rs1799929 0.979 0.988 1.000 1.000
rs1799930 0.906 0.898 0.894 0.777
rs1799931 1.000 1.000 0.941 1.000
rs1456432 rs1048943 rs2470893 rs2472299 rs2470890 rs11854147
rs1456432 1.000 1.000 0.873 0.711 0.405
rs1048943 1.000 1.000 0.944 0.881 0.839
rs2470893 1.000 1.000 0.804 0.956 0.946
rs2472299 0.906 0.951 0.833 1.000 1.000
rs2470890 0.719 0.861 0.914 1.000 0.980
rs11854147 0.510 0.848 0.899 1.000 0.987
rs7246742 rs7250713 rs4105144
rs7246742 0.069 0.746
rs7250713 0.065 0.989
rs4105144 0.807 0.974
b
 D' of affected individuals above diagonal line; D' of unaffecteds below gray line
Chromosome 15 (CYP1A1, CYP1A2 )
Chromosome 19 (CYP2A6 )
a 
D': 0.3-0.6 = Light gray; 0.6-0.8 = Gray; 0.8-1.0 = Dark gray
Chromosome 1 (EPHX1 )
Chromosome 2 (CYP1B1 )
Chromosome 8 (NAT2 )
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Supplementary Table 3. Two-SNP haplotypes by ethnicity 
Gene SNPs Haplotype Freq.
p -
value
Gene SNPs Haplotype Freq.
p -
value
11 0.839 11 0.570
21 0.113 12 0.002
22 0.048 21 0.098
11 0.543 22 0.330
12 0.303 11 0.438
21 0.153 12 0.129
22 0.001 21 0.433
11 0.649 11 0.535
12 0.306 12 0.130
21 0.046 21 0.333
22 0.000 22 0.001
11 0.002 11 0.004
12 0.285 12 0.280
21 0.632 21 0.313
22 0.081 22 0.403
11 0.004 11 0.001
12 0.283 12 0.281
21 0.661 21 0.387
22 0.051 22 0.331
11 0.608 11 0.308
12 0.023 12 0.006
21 0.055 21 0.077
22 0.314 22 0.609
11 0.197 11 0.119
12 0.006 12 0.006
21 0.225 21 0.120
22 0.572 22 0.754
11 0.198 11 0.122
12 0.006 12 0.004
21 0.484 21 0.548
22 0.312 22 0.326
rs163084 
rs10012  
0.179
C
Y
P
1
A
1
rs1456432 
rs1048943  
0.437
rs1456432 
rs2470893  
0.792
rs1048943 
rs2470893  
rs2472299 
rs2470890  
0.658
rs2470890 
rs11854147  
0.089
0.106
rs2472299 
rs11854147  
0.348
rs163084  
rs1056836  
0.761
0.342
rs163084 
rs10012  
0.366
0.279
rs163084  
rs1056836  
A. NHW population B. Hispanic population 
C
Y
P
1
A
2
C
Y
P
1
A
2
rs1456432 
rs2470893  
0.609
rs1048943 
rs2470893  
rs2472299 
rs2470890  
rs2472299 
rs11854147  
C
Y
P
1
A
1
rs1456432 
rs1048943  
0.124
0.416
0.694
rs2470890 
rs11854147  
0.434
C
Y
P
1
B
1
C
Y
P
1
B
1
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Supplementary Table 3. Two-SNP haplotypes by ethnicity (cont.)
Gene SNPs Haplotype Freq.
p -
value
Gene SNPs Haplotype Freq.
p -
value
11 0.202 11 0.122
12 0.005 12 0.002
21 0.479 21 0.576
22 0.315 22 0.300
11 0.405 11 0.211
12 0.008 12 0.030
21 0.275 21 0.464
22 0.312 22 0.295
11 0.410 11 0.229
12 0.007 12 0.009
21 0.268 21 0.472
22 0.315 22 0.291
11 0.677 11 0.667
12 0.002 12 0.002
21 0.002 21 0.029
22 0.319 22 0.301
11 0.245 11 0.123
12 0.045 12 0.070
21 0.314 21 0.533
22 0.125 22 0.274
11 0.249 11 0.175
12 0.040 12 0.013
21 0.561 21 0.576
22 0.149 22 0.236
11 0.681 11 0.653
12 0.147 12 0.004
21 0.128 21 0.097
22 0.044 22 0.246
11 0.245 11 0.380
12 0.045 12 0.017
21 0.585 21 0.542
22 0.125 22 0.061
11 0.249 11 0.360
12 0.040 12 0.036
21 0.561 21 0.451
22 0.149 22 0.153
rs163084 
rs4646429  
0.260
rs10012 
rs4646429  
0.368
rs1051740  
rs2854450  
0.824
rs1056836 
rs4646429  
0.794
0.833
rs7250713 
rs4105144 
0.337
rs7246742 
rs4105144 
rs1051740  
rs2234922  
rs7246742 
rs7250713 
0.344
C
Y
P
2
A
6
rs1056836 
rs10012  
0.273
0.295
rs163084 
rs4646429  
rs1056836 
rs10012  
0.945
rs1056836 
rs4646429  
0.973
rs10012 
rs4646429  
0.497
0.501
0.458
rs7250713 
rs4105144 
0.608
rs1051740  
rs2234922  
rs1051740  
rs2854450  
C
Y
P
2
A
6
rs7246742 
rs7250713 
0.671
0.118
rs7246742 
rs4105144 
0.823
C
Y
P
1
B
1
C
Y
P
1
B
1
A. NHW population B. Hispanic population 
E
P
H
X
1
E
P
H
X
1
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Supplementary Table 3. Two-SNP haplotypes by ethnicity (cont.)
Gene SNPs Haplotype Freq.
p -
value
Gene SNPs Haplotype Freq.
p -
value
11 0.057 12 0.227
12 0.233 22 0.290
21 0.365 11 0.169
22 0.345 21 0.314
11 0.681 11 0.766
12 0.147 12 0.157
21 0.128 21 0.047
22 0.044 22 0.031
11 0.418 11 0.478
12 0.409 12 0.441
21 0.003 21 0.001
22 0.171 22 0.079
11 0.319 11 0.361
12 0.490 12 0.449
21 0.106 21 0.116
22 0.085 22 0.073
11 0.423 11 0.302
12 0.240 12 0.378
21 0.002 21 0.006
22 0.335 22 0.313
11 0.249 11 0.391
12 0.410 12 0.292
21 0.337 21 0.310
22 0.004 22 0.007
11 0.008 11 0.009
12 0.658 12 0.678
21 0.287 21 0.169
22 0.048 22 0.143
12 0.656 11 0.004
21 0.039 12 0.683
22 0.305 21 0.125
11 0.015 22 0.188
12 0.411 11 0.009
21 0.572 12 0.298
22 0.002 21 0.691
22 0.002
rs1051740  
rs360063  
0.993
N
A
T
2
rs2234922   
rs360063  
0.313
0.917
rs1801280 
rs1799929  
0.298
0.964
0.345
0.965
rs1051740  
rs360063  
0.380
rs2234922   
rs360063  
0.350
rs2234922  
rs2854450  
0.146
rs1041983 
rs1799930  
0.861
0.608
0.601
rs1801280 
rs1799929  
rs2234922  
rs2854450  
rs2854450  
rs360063  
rs1041983 
rs1801280  
0.863
rs1041983 
rs1799929  
0.516
rs1041983 
rs1799930  
rs1041983 
rs1799931  
N
A
T
2
E
P
H
X
1
E
P
H
X
1
A. NHW population B. Hispanic population 
rs1041983 
rs1799931  
0.744
rs2854450  
rs360063  
0.307
rs1041983 
rs1801280  
0.384
rs1041983 
rs1799929  
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Supplementary Table 3. Two-SNP haplotypes by ethnicity (cont.) 
Gene SNPs Haplotype Freq.
p -
value
Gene SNPs Haplotype Freq.
p -
value
11 0.002 11 0.010
12 0.421 12 0.302
21 0.291 21 0.174
22 0.285 22 0.514
12 0.425 12 0.311
21 0.038 21 0.130
22 0.537 22 0.560
11 0.296 11 0.174
12 0.292 12 0.523
21 0.002 21 0.010
22 0.410 22 0.292
11 0.037 11 0.126
12 0.550 12 0.572
22 0.413 21 0.001
12 0.298 22 0.301
21 0.038 11 0.003
22 0.664 12 0.179
21 0.128
22 0.690
N
A
T
2
0.284
rs1799930 
rs1799931  
0.880
rs1799929 
rs1799931  
0.403
rs1801280 
rs1799930  
0.605
rs1801280 
rs1799931  
0.737
rs1799929 
rs1799930  
rs1799930 
rs1799931  
0.489
0.185
rs1801280 
rs1799931  
rs1799929 
rs1799930  
0.968
rs1799929 
rs1799931  
rs1801280 
rs1799930  
0.385
N
A
T
2
A. NHW population B. Hispanic population 
0.524
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Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity
Gene SNP Gene SNP Gene SNP Gene SNP
rs1456432 rs2472299 0.19 rs1456432 rs2472299 0.04
rs1456432 rs2470890 0.82 rs1456432 rs2470890 0.67
rs1456432 rs11854147 0.26 rs1456432 rs11854147 0.05
rs1048943 rs2472299 0.33 rs1048943 rs2472299 0.01
rs1048943 rs2470890 0.30 rs1048943 rs2470890 0.07
rs1048943 rs11854147 0.74 rs1048943 rs11854147 0.05
rs2470893 rs2472299 0.56 rs2470893 rs2472299 0.76
rs2470893 rs2470890 0.96 rs2470893 rs2470890 0.79
rs2470893 rs11854147 0.28 rs2470893 rs11854147 0.74
rs1456432 rs7246742 0.09 rs1456432 rs7246742 0.93
rs1456432 rs7250713 0.29 rs1456432 rs7250713 0.36
rs1456432 rs4105144 0.44 rs1456432 rs4105144 0.49
rs1048943 rs7246742 0.91 rs1048943 rs7246742 0.68
rs1048943 rs7250713 0.64 rs1048943 rs7250713 0.07
rs1048943 rs4105144 0.11 rs1048943 rs4105144 0.07
rs2470893 rs7246742 0.85 rs2470893 rs7246742 0.49
rs2470893 rs7250713 0.36 rs2470893 rs7250713 0.69
rs2470893 rs4105144 0.53 rs2470893 rs4105144 0.82
rs2472299 rs7246742 0.72 rs2472299 rs7246742 0.78
rs2472299 rs7250713 0.84 rs2472299 rs7250713 0.51
rs2472299 rs4105144 0.80 rs2472299 rs4105144 0.69
rs2470890 rs7246742 0.31 rs2470890 rs7246742 0.89
rs2470890 rs7250713 0.53 rs2470890 rs7250713 0.95
rs2470890 rs4105144 0.16 rs2470890 rs4105144 0.46
rs11854147 rs7246742 0.81 rs11854147 rs7246742 0.73
rs11854147 rs7250713 0.62 rs11854147 rs7250713 0.66
rs11854147 rs4105144 0.80 rs11854147 rs4105144 0.21
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Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs163084 rs1456432 0.31 rs163084 rs1456432 0.94
rs163084 rs1048943 0.19 rs163084 rs1048943 0.45
rs163084 rs2470893 0.84 rs163084 rs2470893 0.36
rs1056836 rs1456432 0.43 rs1056836 rs1456432 0.52
rs1056836 rs1048943 0.19 rs1056836 rs1048943 0.46
rs1056836 rs2470893 0.36 rs1056836 rs2470893 0.38
rs10012 rs1456432 0.90 rs10012 rs1456432 0.62
rs10012 rs1048943 0.27 rs10012 rs1048943 0.68
rs10012 rs2470893 0.07 rs10012 rs2470893 0.04
rs4646429 rs1456432 0.79 rs4646429 rs1456432 0.72
rs4646429 rs1048943 0.40 rs4646429 rs1048943 0.45
rs4646429 rs2470893 0.09 rs4646429 rs2470893 0.06
rs163084 rs2472299 0.65 rs163084 rs2472299 0.25
rs163084 rs2470890 0.73 rs163084 rs2470890 0.58
rs163084 rs11854147 0.90 rs163084 rs11854147 0.41
rs1056836 rs2472299 0.43 rs1056836 rs2472299 0.05
rs1056836 rs2470890 0.77 rs1056836 rs2470890 0.76
rs1056836 rs11854147 0.52 rs1056836 rs11854147 0.60
rs10012 rs2472299 0.44 rs10012 rs2472299 0.52
rs10012 rs2470890 0.56 rs10012 rs2470890 0.87
rs10012 rs11854147 0.33 rs10012 rs11854147 0.93
rs4646429 rs2472299 0.23 rs4646429 rs2472299 0.84
rs4646429 rs2470890 0.52 rs4646429 rs2470890 0.50
rs4646429 rs11854147 0.42 rs4646429 rs11854147 0.60
rs163084 rs7246742 0.93 rs163084 rs7246742 0.49
rs163084 rs7250713 0.57 rs163084 rs7250713 0.81
rs163084 rs4105144 0.93 rs163084 rs4105144 0.55
rs1056836 rs7246742 0.14 rs1056836 rs7246742 0.32
rs1056836 rs7250713 0.11 rs1056836 rs7250713 0.52
rs1056836 rs4105144 0.02 rs1056836 rs4105144 0.22
rs10012 rs7246742 0.54 rs10012 rs7246742 0.46
rs10012 rs7250713 0.44 rs10012 rs7250713 0.45
rs10012 rs4105144 0.51 rs10012 rs4105144 0.52
rs4646429 rs7246742 0.82 rs4646429 rs7246742 0.39
rs4646429 rs7250713 0.24 rs4646429 rs7250713 0.50
rs4646429 rs4105144 0.35 rs4646429 rs4105144 0.58
C
Y
P
1
A
1
C
Y
P
1
A
2
C
Y
P
2
A
6
C
Y
P
1
B
1
C
Y
P
1
B
1
C
Y
P
1
B
1
B. Hispanic populationA. NHW population
C
Y
P
1
B
1
C
Y
P
1
B
1
C
Y
P
1
B
1
p -
Value
First Locus Second Locus p -
Value
C
Y
P
1
A
1
C
Y
P
1
A
2
C
Y
P
2
A
6
First Locus Second Locus
 
68 
 
Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs163084 rs1041983 0.30 rs163084 rs1041983 0.67
rs163084 rs1801280 0.10 rs163084 rs1801280 0.06
rs163084 rs1799929 0.19 rs163084 rs1799929 0.05
rs163084 rs1799930 0.16 rs163084 rs1799930 0.82
rs163084 rs1799931 0.62 rs163084 rs1799931 0.72
rs1056836 rs1041983 0.76 rs1056836 rs1041983 0.70
rs1056836 rs1801280 0.52 rs1056836 rs1801280 0.04
rs1056836 rs1799929 0.33 rs1056836 rs1799929 0.04
rs1056836 rs1799930 0.32 rs1056836 rs1799930 0.71
rs1056836 rs1799931 0.81 rs1056836 rs1799931 0.47
rs10012 rs1041983 0.98 rs10012 rs1041983 0.57
rs10012 rs1801280 0.40 rs10012 rs1801280 0.17
rs10012 rs1799929 0.46 rs10012 rs1799929 0.12
rs10012 rs1799930 0.35 rs10012 rs1799930 0.86
rs10012 rs1799931 0.58 rs10012 rs1799931 0.66
rs4646429 rs1041983 0.94 rs4646429 rs1041983 0.20
rs4646429 rs1801280 0.52 rs4646429 rs1801280 0.42
rs4646429 rs1799929 0.50 rs4646429 rs1799929 0.44
rs4646429 rs1799930 0.50 rs4646429 rs1799930 0.63
rs4646429 rs1799931 0.52 rs4646429 rs1799931 0.35
rs1051740 rs1456432 0.40 rs1051740 rs1456432 0.92
rs1051740 rs1048943 0.33 rs1051740 rs1048943 0.73
rs1051740 rs2470893 0.89 rs1051740 rs2470893 0.45
rs2234922 rs1456432 0.32 rs2234922 rs1456432 0.87
rs2234922 rs1048943 0.45 rs2234922 rs1048943 0.65
rs2234922 rs2470893 0.72 rs2234922 rs2470893 0.88
rs2854450 rs1456432 0.42 rs2854450 rs1456432 0.51
rs2854450 rs1048943 0.08 rs2854450 rs1048943 0.59
rs2854450 rs2470893 0.59 rs2854450 rs2470893 0.41
rs360063 rs1456432 0.14 rs360063 rs1456432 0.67
rs360063 rs1048943 0.74 rs360063 rs1048943 0.78
rs360063 rs2470893 0.14 rs360063 rs2470893 0.43
N
A
T
2
C
Y
P
1
B
1
C
Y
P
1
A
1
C
Y
P
1
B
1
E
P
H
X
1
First Locus Second Locus
A. NHW population B. Hispanic population
p -
Value
First Locus Second Locus p -
Value
C
Y
P
1
A
1
N
A
T
2
E
P
H
X
1
 
 
 
 
69 
 
 
 
 
Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs1051740 rs2472299 0.55 rs1051740 rs2472299 0.18
rs1051740 rs2470890 0.42 rs1051740 rs2470890 0.98
rs1051740 rs11854147 0.91 rs1051740 rs11854147 0.96
rs2234922 rs2472299 0.46 rs2234922 rs2472299 0.92
rs2234922 rs2470890 0.96 rs2234922 rs2470890 0.74
rs2234922 rs11854147 0.80 rs2234922 rs11854147 0.96
rs2854450 rs2472299 0.40 rs2854450 rs2472299 0.37
rs2854450 rs2470890 0.53 rs2854450 rs2470890 0.73
rs2854450 rs11854147 0.24 rs2854450 rs11854147 0.38
rs360063 rs2472299 0.21 rs360063 rs2472299 0.30
rs360063 rs2470890 0.16 rs360063 rs2470890 0.71
rs360063 rs11854147 0.18 rs360063 rs11854147 0.54
rs1051740 rs7246742 0.07 rs1051740 rs7246742 0.24
rs1051740 rs7250713 0.05 rs1051740 rs7250713 0.29
rs1051740 rs4105144 0.07 rs1051740 rs4105144 0.18
rs2234922 rs7246742 0.05 rs2234922 rs7246742 0.79
rs2234922 rs7250713 0.14 rs2234922 rs7250713 0.42
rs2234922 rs4105144 0.21 rs2234922 rs4105144 0.64
rs2854450 rs7246742 0.99 rs2854450 rs7246742 0.89
rs2854450 rs7250713 0.76 rs2854450 rs7250713 0.18
rs2854450 rs4105144 0.71 rs2854450 rs4105144 0.20
rs360063 rs7246742 0.98 rs360063 rs7246742 0.14
rs360063 rs7250713 0.73 rs360063 rs7250713 0.74
rs360063 rs4105144 0.04 rs360063 rs4105144 0.21
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Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs1051740 rs163084 0.66 rs1051740 rs163084 0.48
rs1051740 rs1056836 0.68 rs1051740 rs1056836 0.55
rs1051740 rs10012 0.38 rs1051740 rs10012 0.44
rs1051740 rs4646429 0.15 rs1051740 rs4646429 0.99
rs2234922 rs163084 0.84 rs2234922 rs163084 0.22
rs2234922 rs1056836 0.58 rs2234922 rs1056836 0.85
rs2234922 rs10012 0.41 rs2234922 rs10012 0.11
rs2234922 rs4646429 0.32 rs2234922 rs4646429 0.12
rs2854450 rs163084 0.88 rs2854450 rs163084 0.55
rs2854450 rs1056836 0.10 rs2854450 rs1056836 0.93
rs2854450 rs10012 0.10 rs2854450 rs10012 0.30
rs2854450 rs4646429 0.13 rs2854450 rs4646429 0.57
rs360063 rs163084 0.46 rs360063 rs163084 0.90
rs360063 rs1056836 0.69 rs360063 rs1056836 0.82
rs360063 rs10012 0.88 rs360063 rs10012 0.12
rs360063 rs4646429 0.82 rs360063 rs4646429 0.08
rs1051740 rs1041983 0.19 rs1051740 rs1041983 0.19
rs1051740 rs1801280 0.03 rs1051740 rs1801280 0.46
rs1051740 rs1799929 0.01 rs1051740 rs1799929 0.40
rs1051740 rs1799930 0.19 rs1051740 rs1799930 0.27
rs1051740 rs1799931 0.98 rs1051740 rs1799931 0.48
rs2234922 rs1041983 0.24 rs2234922 rs1041983 0.73
rs2234922 rs1801280 0.57 rs2234922 rs1801280 0.59
rs2234922 rs1799929 0.97 rs2234922 rs1799929 0.94
rs2234922 rs1799930 0.35 rs2234922 rs1799930 0.51
rs2234922 rs1799931 0.38 rs2234922 rs1799931 0.97
rs2854450 rs1041983 0.78 rs2854450 rs1041983 0.42
rs2854450 rs1801280 0.76 rs2854450 rs1801280 0.24
rs2854450 rs1799929 0.94 rs2854450 rs1799929 0.26
rs2854450 rs1799930 0.82 rs2854450 rs1799930 0.97
rs2854450 rs1799931 0.19 rs2854450 rs1799931 0.69
rs360063 rs1041983 0.21 rs360063 rs1041983 0.89
rs360063 rs1801280 0.47 rs360063 rs1801280 0.65
rs360063 rs1799929 0.41 rs360063 rs1799929 0.48
rs360063 rs1799930 0.10 rs360063 rs1799930 0.87
rs360063 rs1799931 0.29 rs360063 rs1799931 0.53
C
Y
P
1
B
1
N
A
T
2
E
P
H
X
1
E
P
H
X
1
C
Y
P
1
B
1
N
A
T
2
E
P
H
X
1
E
P
H
X
1
A. NHW population B. Hispanic population
First Locus Second Locus p -
Value
First Locus Second Locus p -
Value
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Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs1041983 rs1456432 0.96 rs1041983 rs1456432 0.72
rs1041983 rs1048943 0.85 rs1041983 rs1048943 0.99
rs1041983 rs2470893 0.91 rs1041983 rs2470893 0.46
rs1801280 rs1456432 0.93 rs1801280 rs1456432 0.56
rs1801280 rs1048943 0.61 rs1801280 rs1048943 0.67
rs1801280 rs2470893 0.92 rs1801280 rs2470893 0.15
rs1799929 rs1456432 0.57 rs1799929 rs1456432 0.50
rs1799929 rs1048943 0.60 rs1799929 rs1048943 0.73
rs1799929 rs2470893 0.99 rs1799929 rs2470893 0.06
rs1799930 rs1456432 0.61 rs1799930 rs1456432 0.19
rs1799930 rs1048943 0.53 rs1799930 rs1048943 0.48
rs1799930 rs2470893 0.79 rs1799930 rs2470893 0.61
rs1799931 rs1456432 0.94 rs1799931 rs1456432 0.44
rs1799931 rs1048943 0.65 rs1799931 rs1048943 0.82
rs1799931 rs2470893 0.71 rs1799931 rs2470893 0.92
rs1041983 rs2472299 0.85 rs1041983 rs2472299 0.30
rs1041983 rs2470890 0.91 rs1041983 rs2470890 0.52
rs1041983 rs11854147 0.74 rs1041983 rs11854147 0.36
rs1801280 rs2472299 0.41 rs1801280 rs2472299 0.81
rs1801280 rs2470890 0.61 rs1801280 rs2470890 0.23
rs1801280 rs11854147 0.74 rs1801280 rs11854147 0.50
rs1799929 rs2472299 0.10 rs1799929 rs2472299 0.51
rs1799929 rs2470890 0.40 rs1799929 rs2470890 0.11
rs1799929 rs11854147 0.20 rs1799929 rs11854147 0.30
rs1799930 rs2472299 0.73 rs1799930 rs2472299 0.12
rs1799930 rs2470890 0.92 rs1799930 rs2470890 0.52
rs1799930 rs11854147 0.88 rs1799930 rs11854147 0.58
rs1799931 rs2472299 0.49 rs1799931 rs2472299 0.65
rs1799931 rs2470890 0.51 rs1799931 rs2470890 0.93
rs1799931 rs11854147 0.95 rs1799931 rs11854147 0.92
C
Y
P
1
A
1
C
Y
P
1
A
2
N
A
T
2
N
A
T
2
N
A
T
2
A. NHW population B. Hispanic population
First Locus Second Locus p -
Value
First Locus Second Locus p -
Value
N
A
T
2
C
Y
P
1
A
1
C
Y
P
1
A
2
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Supplementary Table 5. Gene interactions for smoking metabolism genes by ethnicity (cont.)
Gene SNP Gene SNP Gene SNP Gene SNP
rs1041983 rs7246742 0.99 rs1041983 rs7246742 0.19
rs1041983 rs7250713 0.61 rs1041983 rs7250713 0.36
rs1041983 rs4105144 0.21 rs1041983 rs4105144 0.24
rs1801280 rs7246742 0.35 rs1801280 rs7246742 0.42
rs1801280 rs7250713 0.34 rs1801280 rs7250713 0.45
rs1801280 rs4105144 0.40 rs1801280 rs4105144 0.36
rs1799929 rs7246742 0.56 rs1799929 rs7246742 0.22
rs1799929 rs7250713 0.43 rs1799929 rs7250713 0.18
rs1799929 rs4105144 0.26 rs1799929 rs4105144 0.12
rs1799930 rs7246742 0.71 rs1799930 rs7246742 0.23
rs1799930 rs7250713 0.20 rs1799930 rs7250713 0.06
rs1799930 rs4105144 0.04 rs1799930 rs4105144 0.10
rs1799931 rs7246742 0.16 rs1799931 rs7246742 0.16
rs1799931 rs7250713 0.32 rs1799931 rs7250713 0.90
rs1799931 rs4105144 0.33 rs1799931 rs4105144 0.49
C
Y
P
2
A
6
C
Y
P
2
A
6
N
A
T
2
N
A
T
2
A. NHW population B. Hispanic population
First Locus Second Locus p -
Value
First Locus Second Locus p -
Value
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Supplementary Table 6. Results of log-linear regression models for the independent effects of maternal and 
child genotypes 
Mother
p -
value
Child
p -
value
Mother
p -
value
Child
p -
value
rs1456432 0.98 0.32 0.39 0.53 1.12 0.32 1.07 0.53
rs1048943 1.03 0.31 2.73 0.10 1.14 0.31 0.79 0.10
rs2470893 0.20 0.65 1.16 0.28 0.95 0.65 0.88 0.28
rs2472299 2.70 0.10 3.02 0.08 0.84 0.10 0.84 0.08
rs2470890 3.62 0.06 7.77 0.01 1.23 0.06 1.33 0.01
rs11854147 4.46 0.03 2.90 0.09 1.24 0.04 1.19 0.09
rs163084 0.25 0.62 2.07 0.15 0.94 0.62 1.19 0.15
rs1056836 0.16 0.69 2.01 0.16 1.04 0.69 1.15 0.16
rs10012 0.02 0.89 0.37 0.54 0.99 0.89 1.06 0.54
rs4646429 0.01 0.92 0.20 0.65 1.01 0.92 1.05 0.66
rs7246742 2.49 0.11 0.02 0.89 0.83 0.12 1.02 0.89
rs7250713 0.21 0.64 0.03 0.87 1.04 0.65 0.98 0.87
rs4105144 0.04 0.85 1.43 0.23 0.98 0.84 0.87 0.23
rs2854450 0.48 0.49 0.24 0.62 0.92 0.49 0.94 0.62
rs1051740 0.03 0.87 0.05 0.82 1.02 0.87 1.02 0.82
rs2234922 0.35 0.55 2.21 0.14 0.91 0.55 0.81 0.14
rs360063 0.05 0.83 2.79 0.09 1.02 0.83 0.85 0.10
rs1041983 0.49 0.49 0.05 0.82 0.93 0.48 0.98 0.82
rs1801280 0.10 0.76 0.99 0.32 1.03 0.75 1.10 0.32
rs1799929 0.16 0.69 1.28 0.26 0.96 0.69 0.89 0.26
rs1799930 0.07 0.79 0.63 0.43 1.03 0.79 1.09 0.43
rs1799931 0.32 0.57 0.42 0.52 0.91 0.57 0.89 0.52
c 
Relative risk
a
 Log-likelihood
b 
Log-likehood ratio = 2*(LLFull-LLMaternal/Child)   
NAT2
CYP1A2
CYP1B1
CYP2A6
EPHX1
CYP1A1
Gene SNP
LRT
b
RR
c
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Supplementary Table 7.  Nulle allele chi-squared contingency tables 
Proband
Yes No Yes No
WT 33 209 WT 46 321
Null 24 183 Null 11 71
Mom
Yes No Yes No
WT 26 172 WT 46 300
Null 29 181 Null 9 53
Mom Dad Mom Dad
WT 282 183 WT 473 271
Null 281 149 Null 90 62
Mom vs Dad - Hispanic Only
Mom Dad Mom Dad
WT 163 85 WT 259 123
Null 133 60 Null 37 22
Mom Dad Mom Dad
WT 118 96 WT 212 146
Null 145 89 Null 51 40
Mom vs Dad
Maternal Smoking
Allele
X
2
 =0.0469; p = 0.829
X
2
 =0.0402; p =  0.841 X
2
 =0.0672; p = 0.795
Parent
X
2
 = 2.15; p = 0.143 X
2
 =0.301; p = 0.583
Mom vs Dad - NHW Only
Allele Allele
X
2
 = 0.499; p = 0.480 X
2
 =0.600; p = 0.439
Parent Parent
Allele Allele
Allele
GSTM1 GSTT1
Parent Parent
In-utero Exposure
Allele
Maternal Smoking
Allele
In-utero Exposure
X
2
 =0.420; p  = 0.517
Allele
X
2
 =1.03; p = 0.310X
2
 = 2.12; p = 0.146
Parent
Allele
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